What does it cost to outsource accounting work for a Real Estate brokerage in 2024

Only some of the work in a Real Estate brokerage can be outsourced. There is fundamental work that needs to be done locally and in person. But some work with sellers, buyers, and agents doesn't need to be done in person - or doesn't involve interacting directly with clients at all. Accounting is a great example of work that is ideal for outsourcing.

Before examining the cost of outsourcing accounting labor, AccountTECH's team examined what real estate brokerages are spending on labor in 2024. For the first six months of 2024, the average labor cost per agent in Real Estate brokerages was $461.99 per agent per month.

This number represents the total labor cost, including all staff, managers, and executives. Obviously, the accounting department is only a portion of the total labor cost in any brokerage. Additionally, the total labor cost per agent per month varied based on the number of offices, managers, and agents at each company.

Current Labor cost per agent per month

The numbers below show the average Total labor cost per agent per month for the first 6 months of 2024

One important finding is that labor cost per agent begins decreasing as a Company gets bigger. But that trend reverses as a Real Estate company has more than 100 agents. For the larger brokerages, the labor cost of managers and executives increases the unit cost of labor.

Survey results: Outsourced accounting labor cost averages from the AccountTECH survey

AccountTECH finds that generally, when outsourced accounting services are provided to a Real Estate brokerage, the price is generally based on agent count. There is a general assumption that the quantity of accounting work that needs to be performed on a monthly basis is directly related to agent count. For comprehensive outsourcing of all Real Estate brokerage accounting functions, our survey found these average prices as of 8/31/2024.

* for this survey we asked accounting firms to assume the company had only 2 bank accounts and 1 credit card

One of AccountTECH's divisions, BrokerOwnerBooks.com, which provides outsourced accounting services, was included in the nationwide pricing survey.

Analysis

Brokerages are struggling with EBITDA margins (or Return on Revenue margins). One key finding of a recent AccountTECH benchmark study was that labor costs in a Real Estate brokerage tend to be relatively fixed and incapable of adjusting quickly to increases or decreases in either closed transaction count or agent count.

The report results make a strong argument for outsourcing some areas of a Real Estate brokerage operation.

About AccountTECH

For over 25 years, AccountTECH's team of real estate accountants and software engineers have been building tools that increase the efficiency of brokerages. Their latest flagship product is darwin.Cloud - a 4th generation evolution of their popular back office accounting software. The team is constantly adding automation and integrations towards the goal of single-point-of-entry. Their motto is: data entry can happen anywhere, but everything winds up in darwin. In their work with clients, partners and each other, they bring integrity to every interaction and every line of code.

AccountTECH www.accounttech.com (978) 947-3600

For sales inquiries, please contact: Theresa Hurt [email protected] (978) 710-0071

Media contact:Rizza Batol[email protected]978.710.0071

SOURCE AccountTECH

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

CHICAGO, Sept. 18, 2024 /PRNewswire/ -- Waterton, a national real estate investor and operator, today announced the final close of Waterton Residential Property Venture XV, L.P. ("Venture XV") with $1.73 billion of equity commitments from a diverse group of global institutional investors. The fund is one of the largest dedicated multifamily value-add funds in the United States and the firm is poised to invest Venture XV capital through a period of historic pricing disruption.

"We expect to see significant opportunities in the multifamily sector as a result of the current, interest-rate driven disruption and the near-term oversupply in certain markets with healthy longer-term fundamentals," said David Schwartz, chairman and CEO of Waterton. "This fund represents a strong conviction in a sector and a strategy we've been executing for almost 30 years, and a unique cycle-specific opportunity to generate additional alpha in the current market environment."

"Our fundraising success in the midst of a challenging fundraising environment, speaks to our long-term performance as a multifamily specialist and the strong investor relationships we've built over the years," said Michelle Wells, managing partner, investor relations at Waterton. "We are so pleased with the impressive group of global institutional investors we have in the fund – both long term and new partners – and look forward to continuing to invest in what is expected to be a compelling cycle."

Waterton held the first close for Venture XV in December 2022 and selectively pursued investments through 2023. The first deployment for Venture XV was not until October 2023, a 2020-construction, 346-unit high rise building in a core Chicago Loop location. Subsequent acquisitions include a transit-oriented White Plains, NY property 35-minutes from midtown Manhattan; a Seattle-adjacent, garden-style community on the waterfront of Lake Washington, WA and over $100 million in credit-focused investments, including both mezzanine and securitized debt. Recent investment activity has significantly increased with several investments slated to close in September and through the fourth quarter. The capital raise was led by Waterton's in-house investor relations team and Kirkland & Ellis LLP served as legal counsel.

Venture XV will target distressed opportunities as well as traditional value add properties that would benefit from Waterton's vertically integrated design, construction and operations strategy, and plans to invest approximately $5.0 billion in gross assets, including debt, in 30 – 40 multifamily assets across major U.S. markets. Similar to the firm's $1.5 billion predecessor fund formed in 2020, Venture XV will pursue urban and suburban opportunities in major U.S. markets, with an emphasis on well-located, well-maintained workforce housing in markets with favorable job growth, employment metrics and transportation logistics. 

About Waterton:Waterton is a real estate investment and property management company with a focus on U.S. multifamily and hospitality properties. Founded in 1995, Waterton executes value add strategies and manages a national portfolio of properties on behalf of institutional investors, family offices and financial institutions. Waterton is privately held and is headquartered in Chicago with regional teams throughout the United States. As of June 30, 2024, Waterton's portfolio includes approximately $10.0 billion in real estate assets. Visit Waterton's website: www.waterton.com.

Press Contact:Great Ink Communications – (212) 741-2977Sara Williams [email protected]Eric Gerard [email protected]

SOURCE Waterton

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

Presentation details are as follows:

Title: Peripheral Blood and Tumor Gene Expression as Biomarkers and Potential Predictors of Clinical Outcome with HST-1011, an Oral CBL-B Inhibitor
Session Date and Time: Sat., Nov. 9, 2024, 9:00 AM-8:30 PM CTLocation: Exhibit Halls A & B, George R. Brown Convention CenterAbstract Number: 1310

About HotSpot Therapeutics, Inc.HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company's proprietary Smart Allostery platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of cancer and autoimmune diseases. To learn more, visit www.hotspotthera.com.

Investor & Media Contact:Natalie Wildenradt[email protected]

SOURCE HotSpot Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

SAN FRANCISCO, Aug. 27, 2024 /PRNewswire/ -- Hamilton Zanze, a leading San Francisco-based multifamily real estate investment firm, today announced it has sponsored the purchase of The Morris, a 19-story, 344-unit Class A apartment community in Nashville, Tenn. The acquisition closed on Aug. 16.

Hamilton Zanze sponsored the transaction through HZ Capital Partners Fund I, its discretionary fund that targets the acquisition of multifamily properties, alongside joint venture partner Lionstone Investments. Mission Rock Residential, an affiliate of Hamilton Zanze, has assumed management of the property, which is in the heart of Nashville's historic Music Row and immediately proximate to Vanderbilt University and Vanderbilt Hospital.

"We are pleased to sponsor the acquisition of this exceptional multifamily asset," said David Nelson, President and Chief Investment Officer at Hamilton Zanze. "This is a transaction in which our relationships and persistence produced a generational piece of real estate at a time of dislocation in core, infill multifamily. The Morris is well-positioned to capture future growth as supply slows down over the next 18 to 24 months."

Located at 818 19th Ave. South, The Morris was built in 2017 and offers studio, one- and two-bedroom apartment homes. Units range in size from 557 to 1,104 square feet. The homes feature designer finishes, stainless steel appliances, private terraces, 10- to 16-foot ceilings, full-size washers and dryers, hardwood-inspired flooring, floating bathroom counters and plush carpets in the bedrooms. Select homes contain smart-home technology, deluxe wine chillers and exposed concrete ceilings, columns and walls.

"Lionstone's research led us to this location, which scores prominently in our proprietary rating system," said Trisha Mantri, Vice President of Acquisitions at Lionstone Investments. "This investment represents the opportunity to purchase the asset at an attractive basis below replacement cost in a high-growth market."

Community amenities include a rooftop pool with glass overlook, professional-quality music studio, rooftop performance venue, a 19th-floor sky lounge, fitness center, private yoga studio, concierge services, EV-charging stations, pet spa, internet cafe, coffee bar and indoor bike racks.

Located just outside of Downtown Nashville, The Morris offers residents walkable access to the abundant nightlife, restaurants and shopping destinations found in the Music Row and Midtown areas. The community also is notable for its proximity to The Gulch, an urban development on the edge of the Central Business District that features boutique hotels, live music venues, breweries and a diverse array of restaurants.

The Morris sits on the site of country music icon Dale Morris' former office. Morris has represented such major artists as Kenny Chesney, Martina McBride, Alabama and Jake Owen.

This transaction represents Hamilton Zanze's fifth sponsored acquisition of 2024.

About Hamilton ZanzeHamilton Zanze is a private, San Francisco-based real estate investment company that invests with the highest standards. Since its founding in 2001, Hamilton Zanze has sponsored the acquisition of over $6.9 billion in multifamily assets primarily in the Western, Southwestern and Eastern U.S. The company's portfolio currently comprises 124 properties (21,865 units) across 28 markets. For additional information, visit www.hamiltonzanze.com.

SOURCE Hamilton Zanze & Company

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

"We are thrilled to celebrate this industry's top professionals who are hard at work to improve patients' lives. It's our responsibility and our privilege to celebrate the accomplishments and innovation of these incredible people and companies as they drive the world of healthcare forward," says Anna Stashower, CEO and Publisher of PM360. "The Trailblazer winners are changemakers for a variety of conditions, including postpartum depression, lower respiratory tract disease (LRTD), obesity, cortisol dysregulation, epilepsy, and so many more disease areas. We were blown away by the ground-breaking contributions that they have made and the progress they've driven in ensuring access to much-needed medications."

The over 450 attendees were treated to more than just an award ceremony. Actress and comedian Caroline Rhea kept the audience laughing as the emcee and DJ kept the dance party going until midnight.

Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry. The judges are asked to evaluate the following criteria for each category: Company of Year (innovation, talent development, and social responsibility); Brand Champions (innovation, leadership, communication, analytical, and organizational skills); Initiatives (content, format, success in reaching targeted audience, and overall quality); Marketer of the Year (the individual who best exemplifies the most insightful, forward-thinking, and transformative marketing ideas and actions in the industry); Marketing Team (the team who best exemplifies those same qualities); Products of the Year (innovation in treating patients, the uniqueness of the branding strategy, and their ultimate and contribution to the overall healthcare system); CEOs of the Year (ability to thrive in all aspects of leadership including establishing a company culture, displaying a unique vision for their company, and earning respect from industry colleagues due to their morals, reputation, and character); and Lifetime Achievement (an industry veteran who has transformed the business through leadership, wide-ranging influence, and original contributions.)

This year's Lifetime Achievement Award recipient is Adam Schechter, Chairman and CEO of Labcorp. Prior to this role and over his nearly 40-year career, Schechter held a variety of executive, senior, global and U.S.-focused leadership positions at Merck & Co., Inc., spanning sales, marketing, managed markets as well as business and product development. From 2010 to 2019, he served as Executive Vice President and President of Merck's Global Human and Health Division, leading the company's worldwide pharmaceutical and vaccine business, and serving as a member of Merck's Executive Committee. He has made substantial efforts to support the industry and community, with current leadership roles as Board Vice-Chair at the American Clinical Laboratory Association (ACLA), Executive Board Member of the National Alliance for Hispanic Health, and Board Member at Water.org, and DaVita Inc. He has also served on the Boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company.

"Adam Schechter is a global business leader who spent an illustrious career holding senior executive roles and board seats in healthcare industry-leading companies. This diversified his already broad expertise in fields from vaccines to pharmaceuticals and marketing to product development, into a pillar of knowledge," said Anna Stashower, CEO and Publisher of PM360. "His work with LabCorp and other frontrunning organizations, as well as his dedication to world-changing initiatives in areas such as clean water, equal healthcare, and animal health, are all worthy of our Lifetime Achievement Award."

Some of the other big winners include Sumitomo Pharma America, Inc. as this year's Pharmaceutical/Biotech Company of the Year, while embecta was named the Medical Device/Diagnostics Company of the Year and Neurocrine Biosciences, Inc. took home Specialty Pharma Company of the Year. Additionally, Elevate Healthcare was named the Advertising Agency of the Year and GoodRx was given the honor of Supplier/Vendor of the Year. In addition, Ivan Tornos, President and CEO of Zimmer Biomet, was named the Life Sciences Manufacturer CEO of the Year while Judy Capano, Managing Partner and CEO of Calcium+Company, was named the Advertising Agency or Supplier/Vendor CEO of the Year. As for the Brand of the Year, that honor went to Wegovy®.

PM360 will publish profiles of this year's Trailblazer winners in its November issue and on its website.

This year's PM360 Trailblazer winners include:

LIFETIME ACHIEVEMENT AWARD RECIPIENTAdam Schechter, CEO & President (Labcorp)

COMPANY OF THE YEAR: ADVERTISING AGENCYElevate Healthcare

COMPANY OF THE YEAR: MEDICAL DEVICE/DIAGNOSTICSembecta

COMPANY OF THE YEAR: PHARMACEUTICAL/BIOTECHSumitomo Pharma America, Inc.

COMPANY OF THE YEAR: SPECIALTY PHARMA/BIOTECHNeurocrine Biosciences, Inc.

COMPANY OF THE YEAR: SUPPLIER/VENDORGoodRx

ADVERTISING AGENCY OR SUPPLIER/VENDOR CEO OF THE YEARJudy Capano, Managing Partner and CEO (Calcium+Company)

LIFE SCIENCES MANUFACTURER CEO OF THE YEARIvan Tornos, President and Chief Executive (Zimmer Biomet)

MARKETER OF THE YEAR Milana Fomin, Director Patient Marketing (Replimune)

MARKETING TEAM OF THE YEAR SILVER WINNERXDEMVY Consumer Marketing Team (Tarsus Pharmaceuticals)

MARKETING TEAM OF THE YEAR GOLD WINNERCorcept Therapeutics Team (Corcept Therapeutics)

BRAND OF THE YEARWegovy (ConcentricLife)

MOST INNOVATIVE NEW PRODUCTAREXVY Respiratory Syncytial Virus Vaccine, Adjuvanted (Razorfish Health and GSK)

PRODUCT LAUNCH OF THE YEARZURZUVAE® (zuranolone) CIV (Sage Therapeutics and Biogen supported by Weber Shandwick and AbelsonTaylor)

BRAND CHAMPION AWARD WINNERS

Autoimmune/Rheumatology:  Wakim Andre, Head of Marketing, North America (Biocon Biologics)Cardiology: Lali Lobzhanidze, Executive Director, Senior Marketing Strategist, Integrated Marketing (Novartis Pharmaceuticals)Dermatology: Jennifer Novak, Director, Consumer Digital Marketing, (Sanofi)Diabetes/Metabolic Disorders: Ginny Blocki, SVP, Global Marketing & Product Management, (embecta)HCP Engagement: Mayte Cabrera-Dorian, Executive Director, Novartis Patient Support - RLT (Novartis)Hematology/Oncology: Jennifer Monahan, Associate Director Consumer Marketing (Regeneron)Infectious Disease/Vaccine Development: Jackie Messinger, US Head of Marketing Respiratory (Moderna)Innovation/Digital Strategy: Jennifer Spevak, Director, U.S. Vaccines Market Development, Vaccine Portfolio Adherence, Pfizer Men's Health: Katie Lewandroski, Executive Director, Oncology Marketing Lead (Sumitomo Pharma America, Inc.)Ophthalmology/Optometry: Liz Tempesta, Senior Director, Consumer Marketing, Eye Care Division (Viatris)OTC Marketer: Vicky Louit, Director of Medical Marketing, Eucerin® and Aquaphor (Beiersdorf)Patient Engagement: Christine Szymanski, Consumer Strategy Lead, Obesity Marketing, (Novo Nordisk)Rare Diseases: Bryan Burkauskas, Director, US Oncology Marketing WELIREG (Merck)Respiratory: Marc Russo, Associate Director, Interstitial Lung Disease Marketing, (Boehringer Ingelheim Pharmaceuticals, Inc.)Women's Health: Mellisa Hunh, VP Myfembree Marketing Lead (Sumitomo Pharma America, Inc.)

INITIATIVE WINNERS

APP/DIGITAL SOLUTION OR SUITE SILVER WINNERNovoCare® Cost and Coverage (Novo Nordisk and Avalere Health)

APP/DIGITAL SOLUTION OR SUITE GOLD WINNERDon't Sweat Inventory Management (Accord Biopharma, Inc. and Asentech, LLC)

ARTIFICIAL INTELLIGENCE/DATA ANALYTICS INITIATIVE SILVER WINNERAdvancing Care: Harnessing AI to Empower the Hard-to-Reach Patient Audience (argenx, Avalere Health and DxCheck)

ARTIFICIAL INTELLIGENCE/DATA ANALYTICS INITIATIVE GOLD WINNERLOQTORZI DTP + HCP (Cluep, with Confideo Media for Coherus Biosciences)

CONSUMER WEBSITE/ONLINE INITIATIVE SILVER WINNER"Dad Genes" (Johnson & Johnson Innovative Medicine and 21GRAMS, part of Real Chemistry)

CONSUMER WEBSITE/ONLINE INITIATIVE GOLD WINNERDUPIXENT Eczema Skin Gallery Tool (Sanofi, Regeneron Pharmaceuticals, Inc. and EVERSANA INTOUCH)

DIRECT-TO-CONSUMER CAMPAIGN SILVER WINNERThe Season (Weber Shandwick and Sanofi)

DIRECT-TO-CONSUMER CAMPAIGN GOLD WINNERKNOW PLAN GO (FCB Health New York, an IPG Health Company, Real Chemistry, & Starpower, part of Real Chemistry)

DIRECT-TO-PATIENT CAMPAIGN SILVER WINNERSay Yep to VYEPTI (Lundbeck and EVERSANA INTOUCH)

DIRECT-TO-PATIENT CAMPAIGN GOLD WINNERLife without compromise. (BioCryst Pharmaceuticals and Agency: Inizio Evoke Drive)

HCP EDUCATION SILVER WINNERAPDS Awareness: Educating Healthcare Professionals for Better Identification of Patients with the Ultra-Rare Disease (Equals 5, Rare Expertise, and Pharming Group N.V.)

HCP EDUCATION GOLD WINNERSPEVIGO Branded Immersive Presentation (Confideo Labs for Boehringer Ingelheim)

INTERACTIVE/IMMERSIVE MARKETING PROGRAM SILVER WINNERThe CRx Experience Center (ConnectiveRx)

INTERACTIVE/IMMERSIVE MARKETING PROGRAM GOLD WINNERVertex Pharmaceuticals: Helping an Underserved Community Uncover a Deeper Diagnosis (Spectrum Science)

OTC SILVER WINNERReckitt Mucinex Flip the Script inOffice Provider Campaign (InStep Health and Reckitt Mucinex)

OTC GOLD WINNEREucerin® Face Immersive Hydration Launch (Deerfield Agency)

PATIENT/CONSUMER EDUCATION SILVER WINNERTake Care of Your Mental Elf (Spectrum Science)

PATIENT/CONSUMER EDUCATION GOLD WINNERVMS OneVoice — Re-imagining the Ideal Patient Experience (VMS BioMarketing)

PERSISTENCE/ADHERENCE PROGRAM SILVER WINNERTransforming the Customer Experience in Rare Disease to Drive Adherence (Inizio Engage)

PERSISTENCE/ADHERENCE PROGRAM GOLD WINNERKeeping Eliquis Front and Center Among Prescribers and Patients (BMS/Pfizer and ConnectiveRx)

PODCASTS SILVER WINNERUntold Stories: Life with Myasthenia Gravis (argenx, Avalere Health, iHeartRadio, and Ruby by iHeartMedia)

PODCASTS GOLD WINNERSwell Conversations: A Promotional HAE Series (Pharming and Precision AQ)

PROFESSIONAL CAMPAIGN SILVER WINNERReimagine Survival (Biolumina and Takeda Oncology)

PROFESSIONAL CAMPAIGN GOLD WINNERVNS Therapy is a life-changer (LivaNova USA, Inc. and Elevate Healthcare)

SALES AID SILVER WINNERIt's Time to Rescue Rescue Unbranded HCP Campaign (AstraZeneca and VML Health)

SALES AID GOLD WINNERI'm Just a Script: An Rx's Journey from Prescriber to Patient (Xavier Creative House and Johnson & Johnson)

SELF-PROMOTION/CORPORATE CAMPAIGN SILVER WINNERSelf ProMoletion Campaign (SFC Group)

SELF-PROMOTION/CORPORATE CAMPAIGN GOLD WINNERChallenge Accepted (Elevate Healthcare)

SOCIAL MEDIA CAMPAIGN SILVER WINNERPsoriasis Empathetic Language Campaign (dna Communications + Dermavant Sciences, Inc.)

SOCIAL MEDIA CAMPAIGN GOLD WINNERModerna: CMVictory (Spectrum Science)

UNBRANDED CAMPAIGN SILVER WINNERLive With COPD (Sanofi, Regeneron Pharmaceuticals, Inc. and EVERSANA INTOUCH)

UNBRANDED CAMPAIGN GOLD WINNERKnow ESR1 (Menarini Stemline, Biolumina, and Coppola Photography)

VIDEO/TV CAMPAIGN SILVER WINNERSay Yep to VYEPTI (Lundbeck and EVERSANA INTOUCH)

VIDEO/TV CAMPAIGN GOLD WINNERBelieve On (Novo Nordisk and ConcentricLife)

About PM360PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharmaceutical marketing professionals to succeed in the complex and highly regulated healthcare environment.

The journal's targeted and insightful editorial focuses on issues that directly impact critical decision making, including: Planning and implementation of cutting-edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the "360" in the title signifies the span of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read.

By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.

Contact: Gabrielle SmithAssociate Editor, PM360646-300-8113[email protected]

Gabriela L. LaraccaAssociate Editor, PM360646-300-8114[email protected]

SOURCE PM360

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

"We are looking at cutting-edge technology to help shape the future of the building industry," said Jason Dean, SVP of Pro Sales at Oldcastle APG. "We want to align with builders and developers to achieve their customers' dream living spaces, while creating job efficiencies and cost savings."

The build team's goal was to fast-track the three test homes using the efficiency of bagged mortar formulated for the precision of 3D printing.

"We're not just building houses; we're creating homes that elevate living standards with cleaner lines, superior finishes, and greater durability," said Rex Rizk, owner, New Standard Homes. "The goal is to set a new benchmark for sustainable, more affordable housing in architectural styles that folks want to live in."

With a gantry-style 3D printer manufactured by COBOD and leased from PERI 3D Construction, the build team used nearly 150 3,000 lb. bulk bags of Amerimix's AMX300 3D Printing Mix, which was custom-formulated in partnership with the PERI team. According to all collaborating team members, New Standard Homes showed incredible efficiency and resiliency on this project.

The first 1,200 sq. ft. home took approximately six weeks to print, with subsequent 1,500 sq, ft, homes completed in 3 to 3 1/2 weeks. These dramatic speed improvements were realized through continuous optimization of machine setup, layer time and printing speed. And there's more optimization to come.

"New Standard Homes' ultimate goal is to print one 1,500 sq, ft, house per week, which is entirely feasible with our new designs," says Rizk. "Ultimately, concrete is a material that we believe in for its longevity, durability and sustainability. This is the future."

The New Standard Homes team is committed to pushing the boundaries of construction technology. "We are at the forefront of reinventing how our world is built," said Rizk. "This technology is a key component of our vision to provide better homes for everyone."

New Standard Homes is actively evaluating proposals for their next project. Learn more at www.NewStandardHomes.com.

For more information on Amerimix 3D Printing Mixes, visit www.amerimix.com

About Oldcastle® APGOldcastle® APG, a CRH Company, is the leading provider of outdoor living solutions in North America with an award-winning portfolio that enables customers to Live Well Outside. Inspiring endless possibilities with enduring performance, its collection of premier building products create inviting outdoor spaces where people connect, reflect and recharge. Learn more at www.oldcastleapg.com

SOURCE Amerimix

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

"Rise Above" is not just another self-help book; it's a comprehensive toolkit. Readers will discover proven strategies to navigate and overcome obstacles, drawing from Les Brown's extensive experience and insights from the influence of some of the world's top experts like Justin Day. The book is packed with actionable steps that readers can implement immediately to drive success and resilience in their professional and personal lives.

Les Brown's previous books, such as "Live Your Dreams" and "It's Not Over Until You Win," have inspired millions around the globe. These bestsellers have cemented his reputation as a leading voice in personal development, offering timeless wisdom and practical guidance.

From their humble beginnings to becoming one of the most globally influential personalities in the world, both authors’ personal journeys are a testament to the power of perseverance and positive thinking.

Over the decades, their messages of hope and empowerment with countless individuals have helped them to achieve their dreams despite life's challenges.

In the spirit of inspiring others, "Rise Above" is a unique collaboration that draws inspiration from the success stories of some of Les Brown's loyal followers, including Justin Day.

Recognizing the challenges and setbacks faced by many, Brown and his coauthors aimed their contributions to address the specific needs of Les’ followers. This collaborative project integrates this, ensuring the book resonates on a personal level with its readers.

Other notable contributors include:

Rudy Mawer
J Thomas Smith Miranda Walker Diana Leslie Rev Dr Manuel A. Howard Jerry Gibson Barry Cryan Wanda Muir Oliver Stephen Rue Beth Fischer Naima Spencer Dr Tayo Dr Rosemarie Rutecki Dr Michelle Sands

Anticipation is building for the release of "Rise Above: Overcoming Setbacks With Les Brown’s Wisdom," available on Amazon this Fall.

Readers are encouraged to mark their calendars and prepare for a journey of transformation and empowerment!

Follow us on social media for the latest updates, exclusive content, and inspirational messages from Les Brown, Justin Day, and the other co-authors!

Facebook: Les Brown Official X: @LesBrown77 Instagram: @thelesbrown

For more information about "Rise Above" and to pre-order your copy, visit Amazon today!

About Les Brown and Justin Day

Les Brown is a world-renowned motivational speaker, author, and former politician. He has inspired millions with his powerful messages of hope and determination, empowering people to rise above their circumstances and achieve greatness. Brown's dynamic speaking style and profound wisdom continue to make a significant impact globally.

Justin Day, the founder of Day by Day Digital, hails from Dallas, Texas, a bustling business hub that has shaped his entrepreneurial journey.

Beginning his career as a project manager at his mother's agency, Rocket Red, he was inspired to establish his own company, driven by a fierce entrepreneurial spirit.

Over five years at Rocket Red, he self-taught various skills such as web design & development, SEO, content marketing, videography, and email marketing, taking advantage of the dynamic environment to broaden his expertise.

It was this diverse experience that laid the foundation for his independent agency.

One of the standout innovations is his proprietary "Swarm System". It brings together a decade of strategic marketing experience with AI and automated workflows.

This system 'swarms' a client's audience with a perfect storm of content, priming qualified leads and directing them into a sales funnel, ready for purchasing.

Beyond his professional endeavors, he leads a fulfilling personal life.

With his fiancée, and their golden retriever, Ragnar, he loves traveling the world creating content that immortalizes their memories.

An avowed tech-nerd, he spends his leisure time playing video games, listening to audiobooks, and exploring the latest tech products.

Also active in his social life, he relishes playing pickleball and board games with friends during weekends.

His journey, on both a personal and professional level, is a testimony to his perseverance, curiosity, and love for learning.

The founder of Day by Day Digital stands as an example of how anyone can combine passion and expertise, transforming challenges into opportunities for growth and innovation.

Justin DayRise Aboveemail us hereVisit us on social media:InstagramOther

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

September 25, 2024, 11:57 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

This acquisition underscores Baum Family Investments' continued commitment to building a robust portfolio in the Florida market. Over the past few years, the partners of BFI have successfully acquired more than $200,000,000 worth of real estate. This reflects their ongoing strategy to invest in high-value properties with stable, long-term tenants.

In 2024 alone, Baum Family Investments has added four properties to its Florida portfolio, with plans to secure an additional half dozen properties in the coming months. This aggressive acquisition strategy highlights the company's confidence in the Florida real estate market and its dedication to expanding its footprint in the region.

"We are thrilled to add these KFC-leased properties to our growing portfolio," said Aaron L. Baum, Managing Principal at Baum Family Investments. "This acquisition not only strengthens our presence in Florida but also aligns with our strategy of investing in high-quality, income-producing assets."

Baum Family Investments remains focused on identifying and acquiring premium real estate opportunities, with a particular emphasis on properties that offer long-term stability and growth potential.

About Baum Family Investments
Baum Family Investments is a premier real estate investment firm known for its strategic acquisition and management of high-value commercial properties. With a focus on long-term, income-producing investments, the firm has built a diverse portfolio across the United States. Baum Family Investments leverages its expertise to identify and invest in premium properties that offer stability and potential. Its proactive approach and deep market insight position it as a leader in the real estate investment sector.

SOURCE Baum Family Investments

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Details of the upcoming presentations are as follows:

3^rd Annual ROTH Healthcare Opportunities Conference

• Format: Panel - Innovative Therapies for Liquid Tumors
  • The panel will cover the drugs in development by the presenting companies and where they fit competitively for the initial indication as well as for potential subsequent indications, and upcoming data readouts.
• Date: Wednesday, October 9, 2024
• Time: 1:15 – 1:55 PM ET

Panel presentations will be accessible by those registered to attend the conference. In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the event.

2024 Healthcare Virtual Summit, Presented by Maxim Group and hosted by M-Vest

• Format: Fireside chat
• Date: Wednesday, October 16, 2024
• Time: 3:00 PM ET

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member. Click Here to Reserve Your Seat.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas(908) 824-0775[email protected]

SOURCE Moleculin Biotech, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

"We are excited to initiate our first project with the Alliance Industrial team in Laredo, a city rapidly emerging as a key center for cross-border logistics," said John Atcheson, President of ARCO Design/Build Houston and Salt Lake City. "Our partnership with Alliance Industrial and Realterm on this speculative project underscores our commitment to delivering high-quality industrial spaces that cater to the evolving market needs. We look forward to contributing to Laredo's ongoing growth."

The facility will encompass a 236,693-square-foot rear-load concrete tilt-wall warehouse with a 32-foot clear height, 50 dock-high loading positions, and 190 trailer parking spaces. Designed to enhance logistics efficiency, particularly for cross-border trade, the facility is expected to be complete by summer 2025.

As a speculative development, this facility offers potential tenants the advantage of a state-of-the-art logistics space, eliminating the lengthy wait times associated with custom-build projects and positioning Laredo to capitalize quickly on emerging trade opportunities.

Andrew Peeples, Director at Alliance Industrial Company, commented, "Alliance is excited to kick off our first project in Laredo. We are bullish on the nearshoring trend occurring along the Texas border as companies continue to realign their supply chains. The major infrastructure investments Laredo is making ensures leasing activity will remain robust, and we believe the market has a long runway of continued growth for cross-border logistics assets like this one."

Joe Noon, Head of U.S. Development for Realterm, added, "Realterm has been actively investing in the Laredo market for more than 10 years, and we are excited to partner with Alliance Industrial and ARCO on this ground-up development project in this burgeoning market."

ARCO's design-build approach is particularly advantageous for speculative projects like this one, integrating design and construction processes under a single contract. This method allows for greater flexibility to meet potential tenants' needs while maintaining cost-effectiveness and speed of delivery. OneFourTwo Design Group, ARCO's integrated partner for architecture and structural components, ensures seamless coordination between design and construction phases, which is crucial for the successful execution of this project.

The facility is set to enhance Laredo's economic landscape by boosting trade efficiency, creating jobs, and reinforcing the city's role as a pivotal logistics hub. With its strategic location and advanced features, the project is well-positioned to meet the growing demand for cross-border logistics, contributing to the region's long-term growth.

About ARCO Design/BuildARCO Design/Build (ARCO) is widely recognized as a construction industry leader for various industrial project types, including cold storage warehouses, light industrial distribution, and manufacturing. As a national design-build firm, ARCO offers turn-key design-build services that provide a direct relationship with a single point of contact, resulting in cost savings and clear lines of communication. ARCO's capabilities span from project feasibility studies, site selection, and complete design to value engineering, code consulting, and full general contracting. Additionally, ARCO is 100% associate owned as an ESOP. With integrated partners for architectural services and structural engineering, ARCO provides clients with a streamlined and efficient process, ensuring exceptional results.

About Alliance Industrial CompanyAlliance is a privately owned, vertically integrated industrial real estate investment, development and construction company focused on key distribution hubs throughout the US. The firm is headquartered in Houston, TX with offices in Dallas, TX, Phoenix, AZ, Atlanta, GA and Charlotte, NC. Since inception in 2021, AIC has capitalized approximately 5.6M square feet of projects with a total value exceeding $675M with another 5M square feet of projects planned. For more details, visit www.allindustrialco.com

About RealtermRealterm is an independent global investment manager focused on the transportation industry. We acquire, develop, finance and manage differentiated real estate and infrastructure assets serving land, air, sea and rail networks across the world. Realterm currently manages over $11 billion in assets.

SOURCE ARCO Design/Build

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

"For-sale inventory continued to improve in July, which is helping to moderate prices – and hopefully will also ease housing affordability issues over time," said 2024 Florida Realtors^® President Gia Arvin, broker-owner with Matchmaker Realty in Gainesville. "Mortgage interest rates also seem to be trending down off the near 7% highs, which boosts potential homebuyers' purchase power and helps spark demand."

Closed sales of existing single-family homes statewide totaled 23,353, up 5.2% year-over-year, while existing condo-townhouse sales totaled 8,364, down 1.2% over July 2023, according to data from Florida Realtors Research Department in partnership with local Realtor boards/associations. Closed sales may occur from 30- to 90-plus days after sales contracts are written.

Florida Realtors Chief Economist Dr. Brad O'Connor pointed out that, at the end of June, there was a sizeable amount of pending inventory, especially in the single-family home category, which could indicate that closed sales of existing single-family homes would rebound this month.

"And yes, that's what happened," he said. "The increase wasn't enough to offset the decline in single-family closed sales in June, but it was still positive. And, while we came up a little bit short in the townhouse and condo category, July's 1.2% year-over-year decline in closed sales there is far more preferable that what we saw the previous month.

The statewide median sales price for single-family existing homes in July was $416,990, basically the same (up 0.5%) as a year ago, while the statewide median price for condo-townhouse units was $315,000, down 1.3% from July 2023. The median is the midpoint; half the homes sold for more, half for less.

O'Connor pointed out, "Over on the supply side of things, new listings of single-family homes remained in line with what we would have expected in the pre-pandemic market, but there were 10.7% more new listings this July compared to last year's unusually low count. Meanwhile, 13.8% more townhouses and condos came onto the market in July compared to a year ago.

"The inventory of single-family homes continues to rise, but over the last three months, this growth has slowed as each month has passed. I'd caution, however, that this slowdown may be in part just a seasonal effect. Townhouse and condo inventory levels are now above where they were during the 2014 to 2019 pre-pandemic, post-Great Recession period. However, month-over-month inventory growth has flattened out over the past two to three months."

On the supply side of the market, single-family existing homes were at a 4.6-months' supply in July 2024, while condo-townhouse properties were at a 7.4-months' supply.

To see the full statewide housing activity reports, go to the Florida Realtors Newsroom and look under Latest Releases or download the July 2024 data report PDFs under Market Data.

Florida Realtors® serves as the voice for real estate in Florida. It provides programs, services, continuing education, research and legislative representation to 238,000 members in 51 boards/associations. Florida Realtors® Newsroom website is available at http://floridarealtors.org/newsroom.

SOURCE Florida Realtors

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

David E. Feldman is an award-winning filmmaker and the bestselling author of The Dora Ellison Mystery Series. With ten books under his own name and many ghostwritten works, Feldman has established himself as a master storyteller. His first book in the Dora series, Not Today, was a finalist for the Best Mystery 2022 Killer Nashville Claymore award, and is followed by five more thrilling installments.

Now, Feldman is gearing up to release the second book in his new series, Hammer and Sharpe Noir Mystery Thrillers. The first book in the series, Let Thy Children Come, which debuted in May 2024 received a stellar 4.4 rating on Amazon and earned rave reviews from critics and readers alike.

This gripping series starter follows seven-year-old Kyle Robinson, who goes missing just days before Halloween. Private investigator Sam Sharpe, a recovering addict, is hired to find him, leading to a dangerous confrontation with local crime lord Wallace North. At the same time, Judah Hammer, a tough ex-con, grapples with the murder of his father and suspects North’s involvement. The book shows a strong cast of characters, from ruthless killers to femme fatales, and creates a compelling noir mystery.

When asked about the upcoming second book, Feldman teased, "While I can’t reveal much, what I can say it that it will be titled Dead Ringers. I know my readers have high hopes for this series continuation, and I promise they won’t be disappointed."
David E. Feldman consistently impresses audiences with his films and books. For those who haven't yet read Let Thy Children Come, it’s available now on Amazon, and be sure to look out for Dead Ringers, which is coming soon!

More About David In addition to his writing, Feldman has made several films, won two film awards, and won a playwriting contest in 2022. He plays piano and sings professionally, enjoys painting for fun and commission, and cherishes his time with his wife, two sons, and their Yorkie, Boo Bear. Feldman also holds an MLS degree in Library & Information Science.

Donald Harper Press United email us hereVisit us on social media:FacebookInstagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

September 25, 2024, 11:40 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

IRVINE, Calif., Oct. 4, 2024 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces the sixth consecutive year of partnership with Girls Inc. The partnership supports high school and college girls' interest in STEM and mentorship.  

"In 2023, women made up just 28% of the STEM workforce in the United States¹. There are simply too few role models to inspire girls.  Providing them with the opportunity to learn from strong women mentors is one of the most powerful things we can do to help the next generation pursue and succeed in STEM careers," says Carrie Strom, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. "I believe in the power of mentorship – it helps increase education, improve confidence and expand networks that can open doors in the future." 

THE POWER OF MENTORSHIP

The partnership between Allergan Aesthetics and Girls Inc. is aimed to highlight the importance of mentorship and role models in identifying opportunities, addressing challenges and supporting women and girls in STEM.  

Girls Inc. offers mentorship, safe spaces and holistic programming for girls to develop skills and relationships that help them feel safe and excited for their future. 91% of Girls Inc. girls say there are adults at Girls Inc. who believe they will be a success, which research shows is a critical factor in helping to develop their self-confidence and motivation to succeed².

Allergan Aesthetics participates in programs including "Girls Meet the Workforce" with the Orange County Girls Inc. affiliate, mentoring close to 100 girls in four years offering mentees early exposure to working in a professional environment.

"The combination of mentorship, holistic programming, and pro-girl spaces makes the Girls Inc. Experience unique. It is proven to deliver positive outcomes in the lives of girls," said Girls Inc. President & CEO Stephanie J. Hull, Ph.D. "We are grateful to Allergan Aesthetics for being our partners in preparing girls for success. By connecting Girls Inc. participants with women in leadership and career opportunities in a historically male-dominated field, Allergan Aesthetics is helping girls envision themselves in these spaces and equipping them to confidently pursue STEM-related interests."

PLEDGE TO TAKE A MENTORSHIP MOMENT

Allergan Aesthetics will launch an online social campaign to encourage aesthetics professionals and consumers to take a mentorship moment with a girl in their lives in 2024 starting October 4^th – November 8^th.  By simply sharing an Instagram, LinkedIn or Facebook post on Allergan Aesthetics social channels, the pledge represents a promise to take a moment to share their knowledge, skills, and experience with a girl in their life to help them to progress in their career journey. 

In Houston, participants in the Girls Inc. Be Bold LeadHERS Summit at Houston Community College will engage with and learn from the experiences and stories of successful, women physician role models in Houston at the Empower YOU: Equipping the New Generation of STEM Leaders Panel.

CALL TO ACTION

1. Take the pledge by clicking here.
2. For more information to supports girls in your life, go to girlsinc.org/resources-hub to download these free resources, "10 Things You Can Do to Encourage A Girl In STEM" and "Tips for Being an Effective Mentor."

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

About Girls Inc.

Girls Inc. is a network of local organizations that works with schools and in communities across the United States and Canada. Through direct service and advocacy Girls Inc. equips girls – particularly girls from low-income communities and girls of color – with the knowledge and skills to effect positive changes in their lives and to become leaders who will change the world. Professionally trained staff and volunteers provide mentorship, safe spaces, and programming that address the unique challenges girls face and are proven to help girls succeed. Together with partners and supporters, Girls Inc. is building the new generation of leaders. Join us at girlsinc.org.

¹ MIT Professional Education 2024 Research
² 2024 Data from Girls Inc. Research and Evaluation Department

SOURCE AbbVie

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Indxx Inc.

MIAMI, FL, UNITED STATES, September 25, 2024 /EINPresswire.com/ -- Indxx, a provider of indexing solutions for exchange traded funds (ETFs), is pleased to announce the licensing of the Indxx Luxury Goods Top 10 Index to Migdal Mutual Funds Ltd. The Index serves as the underlying benchmark for the MTF Index Fund Indxx Luxury Goods TOP 10 Dollar Hedged (4D), (Ticker: 5139043), which started trading on the Tel Aviv Stock Exchange on September 24.

The Indxx Luxury Goods Top 10 Index is designed to track the performance of the top 10 companies producing and selling luxury goods. The eligible domicile countries are United Kingdom, France, Italy, and Switzerland.

Rahul Sen Sharma, President and Co-CEO at Indxx said, “The growing number of affluent and high net-worth individuals worldwide, particularly in emerging markets, is significantly boosting demand for luxury goods. This expanding demographic, combined with shifting consumer preferences and a heightened desire for quality and exclusivity, is propelling the market's growth. As a result, the luxury goods market is expected to witness a CAGR of 6.8% from 2023 to 2030 and reach $579.26 billion by 2030.¹ Our Luxury Goods Top 10 Index helps capitalize on this opportunity by providing targeted exposure to the top 10 leading companies in this dynamic sector. We are thrilled to collaborate with Migdal Mutual Funds Ltd. to bring this innovative strategy to the Israeli market.”

Vaibhav Agarwal, Chief Product Officer at Indxx, added, “The Indxx Luxury Goods Top 10 Index employs a research-focused methodology to identify the frontrunners in the global luxury goods market. Companies must derive more than 50% of their revenue from the sub-themes: Apparel & Footwear, Automobile Manufacturers, and Accessories to be included. We are delighted to introduce this cutting-edge strategy to the Israeli market in partnership with Migdal Mutual Funds Ltd.”

As of September 25, 2024, the index has 10 constituents. The index has been backtested to December 08, 2017, and has a live calculation date of May 02, 2023. For additional information, please see here.

1. Grand View Research

About Indxx

Founded in 2005 and with offices in the United States and India, Indxx is a leading index provider delivering innovative solutions to the investment management community at large. These range from end-to end indexing services to data and technology products.

Indxx and products tracking its indices have been nominated for and received numerous awards, including ‘Index Provider of the Year’ at the With Intelligence Mutual Fund & ETF Awards 2022 & 2023, ‘Best Index Provider - Emerging Markets ETFs’ at the ETF Express US Awards in October 2020, and ‘Most Innovative ETF Index Provider Americas' at the 14th Annual Global ETF Awards in July 2018.

For more information about Indxx, please visit: https://indxx.com/contact-us

Saakshi Sud
Indxxemail us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

September 25, 2024, 12:09 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

Details of the release are as follows:

News Release: To be released on October 24, 2024. The release will be available over PR Newswire and from SS&C's website at www.ssctech.com. To receive the press release via email immediately after wire distribution, visit investor.ssctech.com and click on Email Alerts.  

Earnings Call: Dial 888-210-4650 (US and Canada) or 646-960-0327 (International) and request the "SS&C Technologies Third Quarter 2024 Earnings Conference Call"; conference ID #4673675.

Webcast: A live webcast of its earnings conference call will be available at the Investor Relations section of SS&C's website, investor.ssctech.com. A replay will be available after the conclusion of the live webcast.

About SS&C TechnologiesSS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 20,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale, and technology.

Additional information aboutSS&C (Nasdaq: SSNC) is available at www.ssctech.com.Follow SS&C on Twitter, Linkedin and Facebook.

SOURCE SS&C

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Since 2018, Capital Square has taken 31 DST offerings full-cycle that have resulted in an average 168.45% total return and an average 12.95% internal rate of return.**

"This is another successful sale of a DST property," said Louis Rogers, founder and co-chief executive officer of Capital Square. "For 12 years, Capital Square has proven a track record of delivering stable returns and appreciation for DST investors."

Located at 775 Gateway Drive SE, Bellemeade Farms is comprised of 12 residential buildings and a clubhouse with a leasing office. The community includes efficiently designed one- and two-bedroom floorplans ranging in size from 583 square feet to 954 square feet. Community amenities include a resort-style pool, outdoor grilling and entertaining area, resident lounge, club room, dog park and spa, tennis courts, 24-hour fitness center with a cardio studio and garden plots available to rent.

Situated on 15.74 acres of land, the community was originally constructed in 1988 and has had $2 million invested in maintenance, landscaping and common areas by prior institutional ownership over the last three years.

"By investing in the DST, Capital Square's investors secured ownership of a large, producing multifamily property in one of the wealthiest counties with significant population growth and a high-ranking school district," said Whitson Huffman, co-chief executive officer. "After five years of sponsoring and managing this investment offering, we are pleased to continue our successful track record and once again deliver a compelling result to investors by taking this DST full-cycle."

Since its founding in 2012, Capital Square has acquired more than 170 real estate assets for over 6,500 investors seeking quality replacement properties that qualify for tax deferral under Section 1031 of the Internal Revenue Code and other investors seeking stable cash flow and capital appreciation.

About Capital SquareCapital Square is a vertically integrated national real estate firm specializing in tax-advantaged real estate investments, including Delaware statutory trusts for Section 1031 exchanges, qualified opportunity zone funds for tax deferral and exclusion and a real estate investment trust (REIT). The company is also an active developer and manager of multifamily communities. Since 2012, Capital Square has completed more than $7.9 billion in transaction volume. Capital Square's mixed-used development projects total over 2,000 apartment units with a total development cost in excess of $800 million, and Capital Square Living, the firm's property management division, now manages over 7,000 apartments across multiple states. Capital Square's related entities provide a range of services – including due diligence, acquisition, loan sourcing, property/asset management and disposition – for a growing number of high-net-worth investors, private equity firms, family offices and institutional investors. The company has been recognized by Inc. 5000 as one of the fastest growing companies in the nation for eight consecutive years. Learn more at CapitalSq.com.

*The "total return" represents the ratio of total sales proceeds and distributions through the life of the asset over the total initial equity invested. The "annualized return" is defined as the difference between net sale proceeds and initial investment, plus the distributions over the holding period, divided by the initial investment; divided by the number of months; times 12. The ROE and annualized return are net of fees and represent a return to an individual investor. These numbers were not audited by a third-party firm. No representation is made that any investment will or is likely to achieve profits or losses similar to those achieved in the past or that losses will not be incurred.

**The audited full-cycle DST track record was calculated as of March 4, 2024. Since that date, three additional DST offerings have been taken full-cycle for a total of 31 DST offerings. Those averages will be calculated the next time the brochure is updated.

Disclosure: Securities offered through WealthForge Securities, LLC, Member FINRA/SIPC. Capital Square and WealthForge Securities, LLC are separate entities. There are material risks associated with investing in DST properties and real estate securities including illiquidity, tenant vacancies, general market conditions and competition, lack of operating history, interest rate risks, the risk of new supply coming to market and softening rental rates, general risks of owning/operating commercial and multifamily properties, short term leases associated with multifamily properties, financing risks, potential adverse tax consequences, general economic risks, development risks, long hold periods, and potential loss of the entire investment principal. Past performance is not a guarantee of future results. Potential cash flow, returns and appreciation are not guaranteed. IRC Section 1031 is a complex tax concept; consult your legal or tax professional regarding the specifics of your particular situation. This is not a solicitation or an offer to see any securities. Please read the Private Placement Memorandum (PPM) in its entirety, paying careful attention to the risk section prior to investing. Private placements are speculative. Diversification does not guarantee profits or protect against losses. FINRA Broker Check link: https://brokercheck.finra.org/.

Contact: Jill Swartz, 949.427.1389, [email protected]

SOURCE Capital Square

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Oct. 4, 2024 /PRNewswire/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among patients under 50. New cases are rising 79% overall, with the fastest rise in windpipe and prostate cancers and the heaviest death toll for cancers of the breast, windpipe, lung, bowel, and stomach. According to the United Nations, cancer rates are set to rise 77% by 2050. In an effort to fight back against cancer, researchers are working on new therapies and making gains, with the FDA issuing 16 oncology approvals between July and September 2024. Behind the scenes, biotech developers are making advancements, with recent market updates coming from: Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), AbbVie (NYSE: ABBV), BeiGene, Ltd. (NASDAQ: BGNE), HUTCHMED (China) Limited (NASDAQ: HCM), and Enliven Therapeutics, Inc. (NASDAQ: ELVN).

According to analysts at Spherical Insights, the global oncology drug market is poised to grow at a CAGR of 11.5% towards US$564.50 billion by 2033. As well, the Global AI in Oncology Market is growing at a rapid 35% CAGR, towards US$13.6 billion by 2032.  

Oncolytics Biotech^® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, recently announced key progress and upcoming studies for its flagship asset pelareorep, an intravenously delivered immunotherapeutic agent in its ongoing trials for breast and pancreatic cancer treatment.

Recent clinical efficacy results from Oncolytics' BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated FDA approval. As well, Oncolytics states in the corporate update that key milestones in its gastrointestinal cancer clinical trials are expected in 2025, with potential for new registration-enabling studies.

"We're excited by the recent BRACELET-1 results, which exceeded our expectations and substantiate the strong efficacy signal previously observed in breast cancer patients treated with pelareorep," said Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors. "Having treated well over 100 HR+/HER2- metastatic breast cancer patients in multiple clinical studies, these results provide the basis for a development path leading to an accelerated approval. The BRACELET-1 results, combined with recent feedback from the FDA, give us confidence in our development approach, and we look forward to initiating a clinical trial designed to support the approval of pelareorep as a novel breast cancer therapeutic."

The strong efficacy results from BRACELET-1 provide the foundation for a large clinical study designed to support an accelerated approval.  Early in 2025, Oncolytics plans to submit to the FDA a pelareorep + paclitaxel combination therapy breast cancer trial.  The study will enroll approximately 180 patients with HR+/HER2- advanced/metastatic breast cancer who have progressed on antibody-drug conjugates (ADCs) like Enhertu, who are not eligible for ADCs, or who cannot tolerate ADCs, which represents a patient population of approximately 55,000 patients in the US.

The study design has sufficient statistical power to deliver a p-value of < 0.05 with a progression-free survival (PFS) benefit of ≥4.3 months. Notably, the BRACELET-1 study demonstrated a 5.7-month benefit for the pelareorep + paclitaxel arm compared to chemotherapy alone. Enrollment in the registration-enabling study is expected to commence in the first half of 2025. 

"With the continuing evolution of breast cancer treatment, we have designed our breast cancer program with the guidance of leading experts in the field," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. "  Our plan is designed to obtain a regulatory approval with fewer patients, in a shorter time, and requiring less funding than traditional regulatory pathways. Our thorough understanding of pelareorep's mechanism of action makes us confident that pelareorep-based combination therapy will continue to deliver strong clinical benefits to HR+/HER- breast cancer patients within the current treatment approach."

Oncolytics anticipates several key milestones in 2025. In the first half of the year, the company plans to initiate a registrational study of pelareorep combined with paclitaxel in HR+/HER2- breast cancer. Also expected in H1 2025 are safety run-in data from cohort 5 of the GOBLET study, which is investigating pelareorep and modified FOLFIRINOX (mFOLFIRINOX), with or without atezolizumab, in newly diagnosed pancreatic cancer, as well as updated efficacy data from cohort 4 of the GOBLET study focused on pelareorep and atezolizumab in second-line or later anal cancer. Once the master protocol has been finalized with the Global Coalition for Adaptive Research (GCAR) for the pelareorep combination therapy, Oncolytics intends to approach the FDA before the end of the year. In the second half of 2025, Oncolytics expects initial efficacy results from cohort 5 of the GOBLET study in pancreatic cancer patients.

CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/

In other industry developments and happenings in the market this week include:

AbbVie (NYSE: ABBV), a leading global pharmaceutical company, recently announced the submission of a Biologics License Application (BLA) to the FDA for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.

With approximately 85% of lung cancers classified as NSCLC, and lung cancer as the leading cause of cancer-related deaths in the world, Teliso-V is being evaluated with patients with a particular type of NSCLC patient with a c-Met protein overexpression that's associated with a poor prognosis.

"Patients with non-small cell lung cancer have unmet medical needs and oncologists are looking for new treatment options for these patients who unfortunately have a poor prognosis," said Roopal Thakkar, M.D., Executive Vice President, Research and Development, Chief Scientific Officer, AbbVie. "We are hopeful that Teliso-V will be a differentiated treatment for certain patients as we look to  elevate the standards of care in oncology."

BeiGene, Ltd. (NASDAQ: BGNE), a global oncology company, recently announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) recognized the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (>1%) and gastric/gastroesophageal junction (G/GEJ) cancers expressing PD-L1 >1%. The committee reviewed efficacy and safety data from the Phase 3 RATIONALE-305 (G/GEJ) and RATIONALE-306 (ESCC) studies, as well as other pivotal studies from the two other PD-1 inhibitors approved in these indications.

"The vote by ODAC members to recommend a class-level cut-off of PD-L1 expression for PD-1 inhibitors used in the treatment of gastric/GEJ cancers and ESCC will help to establish a standard for clinicians and the patients they treat," said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. "We look forward to working with the FDA as it completes its review of our BLAs for TEVIMBRA, and we strive to bring this therapy to applicable patients in the U.S."

HUTCHMED (China) Limited (NASDAQ: HCM), a Hong-Kong-based international targeted therapeutics and immunotherapies developer for cancer and immunological diseases, recently announced that its partner Takeda received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market FRUZAQLA (fruquintinib) for previously treated metastatic colorectal cancer (CRC).

"Takeda has now obtained approval in Japan for FRUZAQLA®, demonstrating the strength of our global data package and the potential of this novel medicine to provide a much-needed treatment option to patients with metastatic CRC," said Dr Weiguo Su, CEO and CSO of HUTCHMED. "Takeda has been a leader in metastatic CRC treatment in Japan for over a decade and we are confident that it is well placed to bring FRUZAQLA® to patients in Japan."

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, recently announced positive data from the Phase 1 clinical trial evaluating ELVN-001, a potent, highly selective, potentially best-in-class small molecule kinase inhibitor, in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (NCT05304377).

"We continue to see categorical improvements in molecular response, and the drug remains well-tolerated with an encouraging safety profile," said presenting investigator Fabian Lang, M.D., from Goethe University Hospital Frankfurt. "Despite recent advancements in the CML treatment paradigm, there continues to be a need for more efficacious and better tolerated active-site TKIs, especially for patients who have failed treatment with allosteric inhibitors. I remain excited to see the progress of ELVN-001 as the trial continues."

Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/

CONTACT:

USA NEWS GROUP[email protected](604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCE USA News Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Exploring Divine Providence and Human Free Will: A Riveting New Novel by John Payne

"Then Comes the Flood" weaves a narrative that confronts real-life dilemmas against the backdrop of spiritual inquiry. The novel addresses the intricate dance between God's sovereignty and human agency, illustrating how even the most challenging moments can be transformed into opportunities for profound personal growth and spiritual enlightenment.

John Payne brings a unique perspective to his writing, blending a successful career in senior management with a deep and abiding commitment to theological study. His professional background includes designing, manufacturing, and marketing commercial wall and roof panel systems, complemented by teaching clinical analyses of these processes. Payne’s lifelong dedication to understanding the Bible through meticulous scripture comparison informs the rich spiritual insights found in his writing. An avid poet and artist, Payne also enjoys crafting English sonnets and creating original oil and watercolor paintings.

Motivated by the complex themes of Calvinism, predestination, and divine foreknowledge, John Payne crafted "Then Comes the Flood" to engage readers with the age-old question: Why do bad things happen to good people? The book examines the impact of life’s trials on personal faith and relationships, offering a narrative that is both enlightening and thought-provoking.

"Then Comes the Flood" promises to leave readers with a renewed appreciation for the mysterious ways in which God operates through human freedom, achieving divine purposes. It presents the miraculous interplay of free will and foreknowledge as a testament to the overarching goodness and intentionality of God’s plan.

"Then Comes the Flood" is available for purchase at all major booksellers, including Barnes & Noble and Amazon. Readers can also find the book through John Payne’s website at https://www.johnpaynebooks.com/.

Atticus Publishing invites readers to explore the depths of human and divine interaction in John Payne’s latest literary achievement, promising a journey that is as intellectually challenging as it is spiritually rewarding.

Atticus Publishing LLC
Atticus Publishing LLC+1 (888) 800-1803email us here

John Payne on The Spotlight Network TV with Logan Crawford

[embed]https://www.youtube.com/watch?v=-0RnP2N7KDY[/embed]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

October 23, 2024, 21:02 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

To commemorate this milestone, Residence Inn Cincinnati Kenwood hosted a ribbon-cutting ceremony welcoming esteemed guests, local dignitaries, and members of the community to celebrate the arrival of this state-of-the-art hotel. The ceremony featured remarks from key executives and local officials, followed by a tour of the property highlighting its modern amenities and spacious suites.     

"We are thrilled to open our doors and welcome guests to the Residence Inn Kenwood," said Trina Wright, general manager of the Residence Inn Kenwood. "Our team is dedicated to providing a home away from home for our guests, ensuring they have a comfortable and enjoyable stay in the heart of Kenwood."

Guests can expect an array of amenities designed to enhance their stay, including fully equipped kitchens in every suite, complimentary breakfast, free Wi-Fi, a fitness center, and a grocery delivery service. The hotel's convenient location offers easy access to nearby attractions such as Kenwood Towne Centre, the Cincinnati Zoo, and various dining options.

The grand opening event signifies not only the debut of a new hotel but also the beginning of a commitment to delivering memorable experiences for both leisure and business travelers visiting the Greater Cincinnati area.

For more information on Residence Inn Kenwood or to make reservations, please visit Residence Inn Kenwood or call 513-745-0429.

About Residence Inn by Marriott

Residence Inn by Marriott is the global leader in the extended-stay lodging segment, with more than 850 properties in over 15 countries and territories. Designed for long stays, the brand offers spacious suites with separate living, working, and sleeping zones. Fully functional kitchens, grocery delivery, 24-hour markets, and complimentary breakfasts help guests maximize their time and thrive while they travel. Each Residence Inn offers free Wi-Fi in both public and guest spaces to ensure continuous connectivity while on the road. For more information or reservations, visit www.residenceinn.com.

About Commonwealth Hotels

Commonwealth Hotels was founded in 1986 and is a proven partner in providing hotel management services with superior financial results.  The company has extensive experience managing premium branded full-service and select-service hotels. Additional information may be found at commonwealthhotels.com 

About Corporex

Corporex Companies is a national, privately held investment and development firm based in Covington, Kentucky. Corporex has a nearly 60-year history of developing world-class hotels, Class A offices, luxury residential, and mixed-use developments in over 22+ states across the U.S. The company has more than $1B in assets under management, has built over 25M square feet, and generously invested in communities with nearly $2.9M in corporate and foundation giving in 2023. Today, the company remains one of the leading privately held, vertically integrated owner/operators of commercial real estate in the country. Learn more at Corporex.com.

ContactBarbara E. Willen Commonwealth Hotels, LLC [email protected]859.392-2254

SOURCE Commonwealth Hotels, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

The securitization pool contains 21 loans collateralized by 74 properties across 15 states for a variety of facilities, including skilled nursing, assisted living, memory care and independent living. The loans had a weighted average LTV of 69% and a weighted average debt yield above 15%.

Structured as a credit risk transfer (CRT), Merchants in collaboration with ATLAS SP Partners as Structuring Agent and Sole Bookrunner, partnered with a large investment manager specialized in alternative assets to purchase the junior securities, which totaled 15% of the transaction. As part of its purchase, the investor retained the first loss Risk Retention certificates as a third-party purchaser.

"Merchants is actively positioning its balance sheet to accommodate potential increased volume during the next couple of years," said Evan Gibson, Executive Vice President of Capital Markets at Merchants Capital. "Merchants has developed a strategic program around loan securitizations, completing four CRTs since 2022, which has helped to provide capital relief, reduce credit risk, and allow Merchants to continue as one of the top multifamily and healthcare bridge lenders in the country."

To learn more about Merchants Capital and its services, visit www.merchantscapital.com or find Merchants Capital on Facebook, X, LinkedIn and Instagram.

ABOUT MERCHANTS BANCORPRanked as a top performing U.S. public bank by S&P Global Market Intelligence, Merchants Bancorp is a diversified bank holding company headquartered in Carmel, Indiana operating multiple segments, including Multi-family Mortgage Banking that offers multi-family housing and healthcare facility financing and servicing; Mortgage Warehousing that offers mortgage warehouse financing; and Banking that offers retail and correspondent residential mortgage banking, agricultural lending, and traditional community banking. Merchants Bancorp, with $18.2 billion in assets and $14.9 billion in deposits as of June 30, 2024, conducts its business primarily through its direct and indirect subsidiaries, Merchants Bank of Indiana, Merchants Capital Corp., Merchants Capital Investments, LLC, Merchants Capital Servicing, LLC, Merchants Asset Management, LLC, and Merchants Mortgage, a division of Merchants Bank of Indiana. For more information and financial data, please visit Merchants' Investor Relations page at investors.merchantsbancorp.com.

ABOUT MERCHANTS CAPITALWith more than 30 years of success built on putting people first, Merchants Capital is a proven leader in financing for multifamily housing nationwide. Our licenses with Fannie Mae, Freddie Mac and HUD/FHA, in addition to our bank's balance sheet products, allow us to offer custom solutions with agility and ease of execution, expanding access to housing in meaningful and impactful ways. Recognized as a top five affordable lender, Merchants Capital pairs our comprehensive debt offerings with in-house tax credit equity to provide a one-stop-shop for developers and owners. To learn more about Merchants Capital, visit www.merchantscapital.com.

FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements which reflect management's current views with respect to, among other things, future events and financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "might," "should," "could," "predict," "potential," "believe," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "goal," "target," "outlook," "aim," "would," "annualized" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about the industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, management cautions that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. A number of important factors could cause actual results to differ materially from those indicated in these forward-looking statements, including the impacts of factors identified in "Risk Factors" or "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K and other periodic filings with the Securities and Exchange Commission. Any forward-looking statements presented herein are made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking statements to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

SOURCE Merchants Bancorp

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

BOSTON, Oct. 4, 2024 /PRNewswire/ -- Healthy.io, the global leader in transforming the smartphone camera into a medical device, is excited to announce its selection as a Finalist for the prestigious 2024 Digital Health Hub Foundation: Digital Health Awards. Healthy.io was selected as a Finalist in the Best in Class - Home Health Diagnostic category, underscoring its leadership in transforming healthcare and promoting health equity. 

This recognition celebrates the company's dedication to democratizing access to kidney testing for at-risk populations. Testing for CKD is desperately needed, as 35 million adults in the US are estimated to have CKD, and approximately 90 percent don't know they have it. Healthy.io's Mintuteful Kidney test, the first FDA-cleared, smartphone-powered kidney test, delivers instant clinical-grade results directly to the user at home, greatly improving both accessibility and convenience of testing for CKD.

The Digital Health Awards shine a spotlight on those making strides in revolutionizing healthcare with cutting-edge digital innovations. As a Finalist, Healthy.io has demonstrated a significant contribution to bridging the larger kidney health equity gap by increasing CKD testing for underserved populations.

"This recognition serves as a significant benchmark in our journey to make kidney testing accessible to all with the help of computer vision, AI, and smartphones," said Geoffrey Martin, CEO at Healthy.io. "We're proud to be named a Finalist in the Digital Health Awards, as this highlights our commitment to bridging the kidney health equity gap and driving innovation in healthcare."

The Awards received over 1,500 submissions this year, with only 150 selected as Finalists. Only four companies in the Best in Class track advanced to this stage.

"Every year, the level of innovation in digital health exceeds expectations, and 2024 has been no exception. The achievements of our finalists represent the most cutting-edge solutions driving healthcare forward," said Mark H. Goldstein, Chairman of the Digital Health Hub Foundation.

Winners will be announced during the Grand Finale at HLTH on October 21, 2024.

About Digital Health Hub Foundation:

Our mission is to support the world's most innovative healthcare companies in scaling and growing. Since 2017, our 30,000-member community has been dedicated to fostering innovation, including early-to-late-stage healthcare companies, industry providers, payors, mentors, and investors. Through our annual awards, we bring together the healthcare industry to celebrate and validate the best of the best in health technology.

About Healthy.io

Healthy.io transforms the smartphone camera into a medical device to deliver healthcare at the speed of life. The company's at-home urinalysis and digitized wound care services enable providers and healthcare systems to close gaps in access and care while increasing patient satisfaction. Healthy.io is a global leader in digital health and is a recipient of the 2023 MedTech Breakthrough 'Best In-Home Testing Solution' Award and the Juniper Research's Digital Health Innovation 'Best Digital Diagnostics Solution' 2023 Award. The company has offices in Boston, London, and Tel-Aviv.

Logo: https://mma.prnewswire.com/media/1856865/Healthy_io_Logo.jpg

SOURCE Healthy.io

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Embracing Identity: A Family’s Path to Understanding and Acceptance

Isabelle Camille, with over three decades of experience in education at Miami-Dade County Public Schools and as an adjunct professor at Miami Dade College, shares her personal and profound journey as the mother of a transgender child. Her book aims to illuminate the multifaceted challenges and triumphs that families face in embracing a loved one's true self. While centered on transgender identity, the story transcends this focus, highlighting the resilience of family bonds against societal challenges.

Holding a Bachelor of Science in Chemistry and a Master of Education from Florida International University, Isabelle’s academic background provides a rich backdrop to the emotional and psychological narratives explored in her writing. Recognized in Marquis Who’s Who, her bilingual fluency in French and Haitian Creole complements her extensive work in community outreach and curriculum development, particularly within educational technology. Her active participation with the YES Institute and other organizations reinforces her dedication to promoting inclusivity and empathy towards transgender individuals and their families.

"The inspiration to write this book came from my own experiences and the realization of the emotional roller coaster parents endure upon discovering their child is transgender," explains Isabelle. "This book is intended to support mothers and families, guiding them through their own journeys of fear and confusion towards a path filled with love and acceptance."

"Sole’s Mom" is an essential read not only for those with personal connections to gender identity issues but also for anyone seeking a deeper understanding of acceptance and familial love in contemporary society. It serves as a powerful reminder of the strength found in letting go and embracing the true essence of family and personal identity.

Atticus Publishing LLCAtticus Publishing LLC+1 (888) 800-1803 email us hereVisit us on social media:Instagram

Isabelle E Camille on The Spotlight Network TV with Logan Crawford

[embed]https://www.youtube.com/watch?v=C0hgIp6mocI[/embed]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

October 23, 2024, 21:00 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

SOLON, Ohio, Sept. 18, 2024 /PRNewswire/ -- MRI Software, a global leader in real estate software and services, has appointed Robb Napolitano as Vice President, Product Innovation. In this role, Napolitano will spearhead the continued growth and evolution of MRI's affordable and public housing solutions, including the recently launched MRI PHA Pro, an integrated solution for public housing and voucher management compliance.

Napolitano, who is based in New York, brings over 17 years of experience in real estate technologies across multiple organizations. In his previous role as Chief Information Officer at The Brooksville Company, he oversaw all information and technology platforms, leveraging technology to reduce costs, improve operational efficiencies, and maximize revenue. His oversight included the largest federally subsidized property in the U.S.: Spring Creek Towers, a 150-acre campus supporting 17,500 residents located in Brooklyn, NY. Earlier, Napolitano held executive positions at industry-leading organizations, including Rose Associates and MAXX Properties.

"Robb has been a longtime client and valued partner for over 12 years, and he joins us at a pivotal moment," said Marc DiCapua, Senior Vice President of Product Innovation for MRI Software. "Robb was an essential collaborator and early adopter of MRI's Affordable Housing product, ensuring that it addressed the evolving needs of the sector. I am excited for the impact his experience will have as he leads MRI's affordable and public housing teams, bringing fresh energy to our subsidized housing product portfolio."

"I've been a strong advocate of MRI's technology for many years, having successfully implemented the solution across multiple organizations," said Napolitano. "MRI is committed to helping PHAs and Affordable housing providers address the challenges of the nationwide housing crisis. The people who serve this industry are passionate about the work they do, and MRI is just as passionate about helping them cultivate thriving communities. I am looking forward to continuing this effort and increasing that momentum."

Napolitano added, "I am also eager to engage with our PHA and Affordable clients at this year's MRI Ascend users conference in San Diego, October 20-23, where we'll share the latest product roadmap and enhancements for the industry."

About MRI SoftwareMRI Software is a leading provider of real estate software solutions that transform the way communities live, work and play. MRI's open and connected, AI-first platform empowers agents, owners, operators and occupiers in commercial and residential property organizations to innovate in rapidly changing markets. MRI has been a trailblazer in the PropTech industry for over five decades, serving more than six million users worldwide, including the public and affordable housing sector. Through innovative solutions and a rich partner ecosystem, MRI gives real estate companies the freedom to realize their vision of building thriving communities and stronger businesses. For more information, please visit mrisoftware.com.

Media Contact for MRI North AmericaRachel Antman[email protected]212-362-5837

SOURCE MRI Software

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

Originally purchased by West for $57 million in 2021, the property gained notoriety when he embarked on an ambitious renovation project that saw extensive alterations, including the removal of flooring, electrical systems, and appliances. Despite West's initial vision, the home remained unfinished and was listed for sale in January 2024 for $53 million. After a price reduction to $39 million in April, Belwood's CEO Bo Belmont recognized an opportunity and made an initial offer of $20 million. Following brief negotiations, the final sale price was agreed upon at $21 million, with escrow closing on September 26, 2024.

Belwood Investments plans to restore the property to its original design as envisioned by renowned architect Tadao Ando. To ensure a successful transformation, the firm will enlist the expertise of Marmol Radziner, the original architectural firm contracted to develop the project for previous owner Richard Sachs. This partnership highlights Belwood's commitment to quality and authenticity in high-end real estate restoration.

"Acquiring this iconic property is a testament to our dedication to providing exceptional investment opportunities," said Bo Belmont. "Our goal is to restore this home to its full potential while making luxury real estate accessible to a broader audience. We believe that investing in real estate should be exciting, and we're looking forward to sharing this journey with our investors."

Belwood Investments sets itself apart in the real estate market by offering everyday individuals the chance to acquire fractional ownership in premium properties via a user-friendly mobile app. Opportunities start as low as $1,000, and each ownership share is backed by a Deed of Trust, ensuring that participants' contributions are directly connected to the property. With a solid history of delivering significant returns, the company has earned a reputation as a leader in fractional real estate ownership.

Since its establishment in 2018, Belwood has rapidly evolved from its humble beginnings in Folsom, CA. Two years ago, the company opened an office in Huntington Beach, CA, and has recently relocated to a larger office in Newport Beach to facilitate further expansion. This strategic move positions Belwood to continue exploring new real estate investments while enhancing the offerings available to its investors.

"We're excited to announce that we have some fun updates coming to our app, which will not only introduce new investment opportunities but also provide features that make real estate investing more engaging and immersive," added Belmont. "Belwood's B52 Model takes away the headaches and stress typically associated with traditional fix-and-flip methods, allowing our investors to enjoy the returns without the hassle."

Belwood Investments is committed to expanding its portfolio of premium properties, continuously seeking out exceptional opportunities that offer significant investment potential. With a focus on quality, community, and innovation, Belwood aims to redefine how everyday individuals can participate in the luxury real estate market.

For media inquiries, please contact:

David Contreras
Belwood Investments323-251-6855[email protected] www.belwoodinvestments.com

SOURCE Belwood Investments

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

The Research Institute at the Hospital for Endocrine Surgery opens just 2.5 years after the opening of the new state of the art endocrine hospital which specializes in curative surgery for tumors of the thyroid, parathyroid and adrenal glands. Thyroid cancer  is one of the fastest-growing cancers globally, with a particularly high incidence among women. The new Research Institute will serve as a hub for groundbreaking research and innovative clinical trials that aim to advance the understanding, diagnosis, and treatment of thyroid cancer and other endocrine diseases.

"We are excited to leverage our position as the highest-volume thyroid surgeons in the world to drive significant advancements in thyroid cancer research," said Dr. Gary Clayman, founder of the Clayman Thyroid Center. "With over 2,000 thyroid cancer operations performed annually, our unmatched patient volume uniquely positions us to expedite clinical trials, bringing cutting-edge treatments to patients more quickly and unlocking new insights into the biology and treatment of thyroid cancers."

Fabio Faucz, PhD was recruited from his leadership position at the NIH to lead the Research Institute. "This Institute represents a significant step forward in our fight against thyroid cancer and other endocrine diseases. Our goal is to foster a collaborative environment where innovative ideas can flourish, and where our research can translate into tangible benefits for patients. We are committed to pushing the boundaries of what is possible in thyroid cancer treatment and research, and I am honored to lead this initiative."

The new Research Institute will have a heavy emphasis on cancer genetics with the development of the world's largest biobanking of thyroid cancers allowing for personalized cancer treatments based upon individual cancer genetics. By accelerating the pace of research, the Institute is committed to transforming the landscape of thyroid cancer care and offering new hope to patients worldwide.

The Clayman Thyroid Center's surgeons operate exclusively at the Hospital for Endocrine Surgery in Tampa, Florida alongside their sister surgeons of the Norman Parathyroid Center and the Carling Adrenal Center. Together, they are the highest volume endocrine surgery practice in the world which will provide the Research Institute unprecedented access to thyroid, parathyroid and adrenal tumors.

About the Clayman Thyroid Center:
Founded by one of the nation's best-known thyroid surgeons, the Clayman Thyroid Center is the highest volume thyroid cancer referral center in the United States. The Center boasts the most experienced thyroid surgeons in the US who provide personalized care allowing the greatest opportunity for cancer cure, wellness, and cosmetic, and functional, outcomes via all types of thyroid surgery from minimal incision to scarless thyroid surgery to advanced cancer care.www.thyroidcancer.com | (813) 940-3130

About the Hospital for Endocrine SurgeryThe Hospital for Endocrine Surgery is a campus of HCA Florida South Tampa Hospital focused on compassionate patient care and highly specialized treatment of endocrine tumors. We provide a wide array of services necessary for the diagnosis and surgical treatment of tumors of the thyroid, parathyroid, and adrenal glands. Our team includes doctors, surgeons, nurses, and technicians who have dedicated their careers to delivering the highest cure rates using the most advanced techniques available. HCA's Hospital for Endocrine Surgery is the nation's highest-volume hospital for thyroid, parathyroid, and adrenal tumors and cancers.www.hospitalforendocrinesurgery.com 

Media Contact:Julie Canan, Director of Marketing941.468.3002 | [email protected]

SOURCE Clayman Thyroid Center

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

"We are excited to add this Long Island City warehouse into our growing New York City Boroughs portfolio," said Brian Tozer, Vice President. "This location provides excellent accessibility into Manhattan while the property's building to land ratio is ideal for the type of tenant demand that we see in the Boroughs. It offers a 10,033 SF single tenant building with 5,000 SF of secured off-street parking, which is a highly desired amenity, particularly in this location within Long Island City. This acquisition perfectly aligns with our investment strategy, to secure well-located, functional warehouses in targeted neighborhoods that are well suited for service and distribution throughout NYC. We continue to seek investment opportunities to further increase our portfolio concentration throughout the Boroughs."

This is the Company's first investment in the Long Island City submarket and expands the Company's existing New York City Boroughs portfolio to 1.3 million square feet across 61 properties.

For more information about this property, please contact Brian Tozer at [email protected]

About Seagis Property Group Seagis Property Group is a privately held real estate owner focused on the acquisition and development of industrial properties in global logistics hubs along the Eastern Seaboard. The company's portfolio spans 12 million square feet of space and includes 190 buildings in New Jersey, New York City, and South Florida. Seagis acquires core, value-add and development real estate for warehouse/logistics use. The company was founded in 2005 and is headquartered in Conshohocken, Pennsylvania. For more information, visit www.seagisproperty.com

SOURCE Seagis Property Group LP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

"The 2024 HousingWire Vanguards represent the pinnacle of leadership in our industry, driving transformative growth within their organizations and setting new standards for excellence," said HW Media Editor-in-Chief Sarah Wheeler. "These extraordinary leaders embody the innovative spirit and resilience crucial for navigating today's dynamic housing landscape. Their groundbreaking achievements highlight the profound impact of visionary leadership, making the Vanguards award a career-defining honor reserved for the very best in our field."

Curbio's mission is to make listing market prep hassle-free for agents so they can have more time to build client relationships, win listings, and sell more homes at better prices. Curbio is evolving the outdated, obstacle-ridden process of pre-sales improvements into a simplified, full-service experience powered by technology. Curbio streamlines how agents get listings ready for sale, offering quality pre-listing home repairs and updates with no money due from sellers until closing. It uses market and project data to generate same-day estimates, followed by personalized proposals reflecting the right scope for a listing. Curbio's app offers agents and sellers instant communication and updates directly to their phones for complete visibility. Curbio has worked with thousands of agents from some of the most respected brokerages in real estate to bring a streamlined, supportive experience to sellers across the country.  

"The HousingWire Vanguards award recognizes the most outstanding executive leaders in mortgage and real estate — executives who make a real impact by driving innovation, setting strategic direction, and steering their organizations toward monumental achievements," said Clayton Collins, CEO of HW Media. "These leaders play a crucial role in shaping the industry's future, with far-reaching impacts on market trends, operational efficiencies, and overall industry success. By leading with vision and decisiveness, HousingWire Vanguards propel their companies toward success and significantly influence the broader landscape of the housing economy."

Additional information and full list of this year's winners can be found at https://www.housingwire.com. For more information about Curbio, please visit, www.curbio.com.

About CurbioCurbio is the leading provider of home repairs and improvements for real estate agents getting their listings ready for sale. With a turnkey approach and a simple pay-at-closing model, Curbio specializes in pre-listing home updates of any size.  Curbio streamlines the fragmented and time-consuming home improvement process into an efficient, full-service experience for agents and their clients thanks to dedicated project managers, in-demand materials, quality work, and proprietary technology. Curbio is trusted by thousands of respected agents and brokers from companies including eXp Realty, RE/MAX, Berkshire Hathaway Home Services, Compass, National Association of REALTORS®, and Leading Real Estate Companies of the World.

SOURCE Curbio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

According to Dwight Kay, Managing Member and Founding Partner of Cove Capital Investments, the property was purchased by Cove Capital as part of its growing portfolio of debt-free Delaware Statutory Trust real estate assets for 1031 exchange and direct cash investors.

"The asset, located in the income tax-free state of Texas, was newly constructed in 2023. It features a 15-year corporate net lease with multiple extension options and rent increases every five years during the primary term and options." said Dwight Kay, Managing Member and Founding Partner of Cove Capital Investments. "The tenant has a market cap of over $20 billion dollars, is publicly traded and holds an investment grade credit rating," said Kay. ¹

"We are excited to introduce another quality, debt-free DST real estate investment option. The tenant, considered an essential business, paid rent throughout the COVID-19 pandemic. They employ over 40,000 people, operate more than 1,900 stores across 49 states, and generated total revenue of over $14 billion dollars in 2023.," said Chay Lapin, Managing Member and Founding Partner of Cove Capital Investments.²

The property is in Texas, a pro-business and income tax-free state as well is strategically situated in Quinlan, TX, the asset is highly visible and is directly off Highway 276. The area also boasts an average household income of over $77,000 within five miles of the property. Additionally, it serves as the gateway to the 376-acre Lake Tawakoni State Park, offering a 200-mile shoreline.³

"This investment highlights our dedication to acquiring quality assets in strategic locations that provide investment potential for our investors. We look forward to our ownership period and are honored to add this location to our portfolio of nearly 2.5 million square feet," said Kay.

Like many of Cove Capital's real estate acquisitions, the Cove Tractor Net Lease 79 DST was acquired with 0% leverage for those investors who want to potentially mitigate risk by investing in a debt-free DST offering with no risk of lender foreclosure or lender cash flow sweeps.

Sources:
^{1, 2 and 3} Offering Memorandum

About Cove Capital Investments

Cove Capital Investments is a Delaware Statutory Trust sponsor company that operates a portfolio of over 2.4 million square feet of real estate in 33 states nationwide.  Over 1,800 investors have trusted Cove Capital with their 1031 exchange and investment dollars, many of them being repeat investors in multiple DST offerings over the years. Our offerings are attractive to those investors seeking to lower risk potential as the majority of Cove Capital's DST offerings are debt free (no mortgage - no lender foreclosure risk).  To sign up for a list of the current Cove Capital offerings available for 1031 exchange and direct investments please visit www.covecapitalinvestments.com.

For further information, please visit www.covecapitalinvestments.com or contact Cove Capital at (877) 899-1315 and via email at [email protected].

*Past performance is no guarantee of future results.

*Diversification does not guarantee profits or protect against losses.

*This material does not constitute an offer to sell nor a solicitation of an offer to buy any security. Such offers can be made only by the confidential Private Placement Memorandum (the "Memorandum"). Please read the entire Memorandum paying special attention to the risk section prior to investing. This material contains information that has been obtained from sources believed to be reliable. However, Cove Capital Investments, LLC does not guarantee the accuracy and validity of the information herein. Investors should perform their own investigations before considering any investment. IRC Section 1031, IRC Section 1033 and IRC Section 721 are complex tax codes therefore you should consult your tax or legal professional for details regarding your situation. This material is not intended as tax or legal advice. There are material risks associated with investing in real estate, Delaware Statutory Trust (DST) properties and real estate securities including illiquidity, tenant vacancies, general market conditions and competition, lack of operating history, interest rate risks, the risk of new supply coming to market and softening rental rates, general risks of owning/operating commercial and multifamily properties, short term leases associated with multi-family properties, financing risks, potential adverse tax consequences, general economic risks, development risks and long hold periods. There is a risk of loss of the entire investment principal. Past performance is not a guarantee of future results. Potential cash flow, potential returns and potential appreciation are not guaranteed. For an investor to qualify for any type of investment, there are both financial requirements and suitability requirements that must match specific objectives, goals and risk tolerances. Securities offered through FNEX Capital, member FINRA, SIPC.

SOURCE Cove Capital Investments

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Teleradiology Market

Teleradiology Market size was valued at USD 9.58 billion in 2023 to USD 30.13 billion by 2031, growing at a CAGR 15.40% during the forecast period (2024-2031).

WESTFORD, MA, UNITED STATES, September 25, 2024 /EINPresswire.com/ -- Global Teleradiology Market size was valued at USD 8.30 billion in 2022 and is poised to grow from USD 9.58 billion in 2023 to USD 30.13 billion by 2031, growing at a CAGR of 15.40% during the forecast period (2024-2031).

The increasing use of digital technologies in the healthcare industry is projected to primarily set the tone for teleradiology market growth going forward. The rising use of telemedicine and teleconsultation practices in the healthcare industry is also boosting the adoption of teleradiology. The surge in the number of medical imaging diagnostic procedures around the world is also driving up the demand for teleradiology.

Teleradiology market players are projected to invest heavily in the research and development of novel products and services to enhance their business scope. Teleradiology providers are focusing on fulfilling the massive surge in demand for medical imaging around the world through their offerings to boost revenue.

Get a Free Sample Research Report:
https://www.skyquestt.com/sample-request/teleradiology-market

Teleradiology Market Segmental AnalysisGlobal Teleradiology Market is segmented by Product & Service, Imaging Technique, End User, and region.

Based on Product & Service, the market is segmented into Teleradiology Services, Software, and Hardware. Based on Imaging Technique, the market is segmented into computed tomography, Magnetic Resonance Imaging (MRI), Ultrasound, X-ray, Mammography, Nuclear Imaging, Fluoroscopy. Based on End User, the market is segmented into Hospitals And Clinics, Diagnostic Imaging Centers and Laboratories, Long-term Care Centers, Nursing Homes, & Assisted Living Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Partnerships and Acquisitions Remain Preferred Strategies for Teleradiology Companies Back in August 2023, a medical imaging SaaS organization known as OnePacs was acquired by Experity. The move helped Experity strengthen its teleradiology portfolio and cements its high market share as a top teleradiology provider in the United States. OnePacs’ leading PACS platform will help Experity offer a fully tech-enabled teleradiology solution for users.

Recently in January 2024, Radsource LLC, a renowned name in orthopedic and neurological MRI interpretations received investment from HealthEdge Investment Partners LLC. This move helped HealthEdge mark its entry into the teleradiology market to capitalize on the rising demand for medical imaging around the world.

Teleradiology companies are leveraging collaborations and acquisitions to improve their market share and presence around the world. These strategies are especially beneficial for established teleradiology companies as they have the resources and capital to make the most out of them. However, new companies with innovative approaches can also benefit from these strategies if they play their cards right.

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/teleradiology-market

This report covers the following players: • GE Healthcare (US) • Medica Group PLC. (UK) • Cerner Corporation (US) • McKesson Corporation (US) • Agfa Healthcare (Belgium) • Siemens Healthineers (Germany) • Fujifilm Holdings Corporation (Japan) • 4Ways Healthcare (UK) • Teleradiology Solutions (India) • ONRAD (US) • RamSoft, Inc. (Canada) • Novarad Corporation (US) • TeleDiagnostic Solutions Pvt. Ltd. (India) • StatRad LLC (US) • Medweb LLC (US) • Nautilus Medical (US) • Mirada Medical (UK) • Telerad Tech (India) • USARAD Holdings, Inc. (US) • Koninklijke Philips N.V. (Netherlands) • InHealth Group Ltd. (UK)

Addressing Shortage of Radiologists through Teleradiology - Key Opportunity Over the DecadeYellowcross Healthcare Commerce, a new company focused on practice management for healthcare professionals and organizations launched a new service to streamline teleradiology service management in February 2024. The company works with different healthcare establishments to understand and meet their teleradiology needs.

Insightiv Technologies, a technology start-up from Rwanda is leveraging the use of artificial intelligence (AI) to address the shortage of radiologists. The company is achieving this by combining AI with teleradiology to provide insights into radiology reports for hospitals without radiologists. The images are sent to remote radiologists for insights and help in promoting better diagnosis for patients.

Addressing the shortage of radiologists around the world will be a key opportunity for teleradiology companies. The use of artificial intelligence and other technologies will provide a highly rewarding new business scope for teleradiology providers as they work towards resolving the issue pertaining to the absence of skilled radiologists amid growing demand for medical imaging.

View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/teleradiology-market

This report covers the following segments: A. Product & Service1. Teleradiology Services2. Software [Picture Archiving & Communication Systems (PACS), Radiology Information Systems (RIS)]3. Hardware4. OthersB. Imaging Technique1. Computed Tomography2. Magnetic Resonance Imaging (MRI)C. End User 1. Hospitals And Clinics2. Diagnostic Imaging Centers and Laboratories3. Long-term Care Centers4. Nursing Homes & Assisted Living Facilities5. Other End Users

Teleradiology companies have multiple opportunities to explore as the demand for medical imaging increases. The simplest way to maximize business growth for market players would be to address the challenges in radiology and solve them using teleradiology. The use of advanced technologies will be an unmissable trend for teleradiology of the future.

Related Report:Mammography Market is growing at a CAGR of 10.1% in the forecast period (2024-2031).

About Us:SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Visit Our Website: https://www.skyquestt.com/

Mr. Jagraj SinghSkyquest Technology Consulting Pvt. Ltd.+1 351-333-4748email us hereVisit us on social media:LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

September 25, 2024, 13:30 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

Sammamish ‒ a highly desirable suburb east of Seattle situated between Bellevue, Redmond, and Issaquah ‒ offers an irreplaceable combination of top tier school districts, access to local employers and proximity to some of Washington's most desirable nature. While its population has grown quickly over the past 20 years, the city has historically been, and is forecasted to continue, being one of the most supply insulated submarkets in the entire Seattle metropolitan area. This has caused the barrier to entry to be extremely high, with median home values exceeding $1.6 million. Consequently, the median household income in Sammamish is about $215,000 higher than any other US city with a population over 50,000.

SKY Sammamish is located along 228th Ave., the city's primary north and south thoroughfare with access to both I-90 (to the south) as well as SR-202 (to the north). The property was developed as a phase of the expanding Sammamish Town Center ‒ a multi-phase, mixed-use development project that will serve as the new town center for Sammamish. The property is the only housing located within the town center development and sits adjacent to a variety of commercial spaces, retail, and food options. Most notably, the site is adjacent to Metropolitan Market, an upscale Seattle-based grocery chain.

The business plan is a core-plus investment with moderate upgrade characteristics. While the asset currently offers a best-in-class amenity package and well-appointed living units, Security Properties has identified several opportunities to further emphasize these strengths.

According to Alex Gauper, Senior Director at Security Properties, the acquisition was made because, "SKY Sammamish is a prime example of our firm's investment thesis of identifying newer-vintage assets in markets with high barriers to entry and a diverse mix of stable drivers. We feel that we have the best asset in a submarket with a very limited historical supply, excellent schools, and strong demand for high-quality housing. The Issaquah and Sammamish submarket has been a strong performer for us for many years and we are excited to add to our existing portfolio in the area."

The property will be managed by Security Properties-affiliate Security Properties Residential.

About Security Properties

Security Properties is a national real estate investment, development, and operating company headquartered in Seattle, Washington. For more than 50 years, Security Properties has provided quality housing to its residents as well as excellent financial performance for its investors. Since its founding, Security Properties has acquired or developed over 108,000 residential units at a cost of over $11.8 billion across more than 650 assets. Security Properties maintains a focused multi-family strategy supported by integrated teams of professional acquisition, development, construction, investment, and property management specialists. For more information, visit www.securityproperties.com

About Security Properties Residential

Security Properties Residential is the affiliated property management firm of Security Properties, created to increase the value of its real estate holdings by more closely managing its assets. Operating throughout the Western United States and select markets, Security Properties Residential is committed to delivering exceptional service to its apartment communities and residents. Services include property, construction, and compliance management services that create positive living environments for residents and build value for clients.

News media contact:
Ed McGovern, (206)-622-9900[email protected] 

SOURCE Security Properties

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

LiveDeal is designed to streamline the deal-sourcing process for lenders. It offers an intuitive, tech-forward solution that allows lenders to explore and evaluate potential deals in real-time. The platform is built for lenders, giving them the ability to filter deals based on key metrics such as loan type, loan amount, property type, and location. With the ability to view deal summaries at a glance, lenders can quickly assess opportunities and express interest in the ones that match their investment criteria.

"Our goal is to maximize deal exposure for our clients while providing lenders with a seamless experience," said Chris Pepe, CEO of LoanGeek. "Traditionally, we've worked directly with lending partners to source financing. With the launch of LiveDeal, we are inviting lenders to be part of the process from the start, increasing efficiency and ensuring they have access to the best deals."

Key features of LiveDeal by LoanGeek include:

• Advanced Deal Filtering: Lenders can filter deals by location, loan type, loan-to-value (LTV), and other metrics, enabling them to quickly find the most relevant opportunities.
• Instant Notifications: When lenders express interest in a deal, the LoanGeek team is immediately notified, ensuring quick follow-up and detailed discussions about the transaction.
• Real-Time Updates: LiveDeal offers live updates, so lenders are always working with the most current information on each deal.

LiveDeal by LoanGeek offers a significant step forward for lenders seeking efficiency in deal sourcing. It's designed for lenders who want an efficient way to discover high-quality opportunities, making it the most effective platform for sourcing and evaluating deals in today's competitive market.

About LoanGeek:LoanGeek is a commercial real estate financing platform specializing in connecting real estate investors with capital providers. Serving the commercial real estate industry, LoanGeek's platform streamlines the process for both lenders and borrowers.

For more information, visit www.loangeek.com

SOURCE LoanGeek, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

DNA Sequencing Market

Global DNA Sequencing Market size is going to reach USD 44 billion by 2031, growing at a CAGR of 17.12% in the forecast period (2024-2031).

WESTFORD, MA, UNITED STATES, September 25, 2024 /EINPresswire.com/ --
Global DNA Sequencing Market size was valued at USD 10.5 billion in 2019 and is poised to grow from USD 12.29 billion in 2023 to USD 44 billion by 2031, growing at a CAGR of 17.12% in the forecast period (2024-2031).

DNA sequencing technology has tremendous potential in clinical research and development for cancer diagnosis and treatment. More recently, experimental next-generation sequencing (NGS) technologies have demonstrated their potential as a high-throughput and cost-effective method for identifying and characterizing feasible genetic variants. DNA sequencing methods have evolved over time to produce high-quality results and be used in clinical laboratories and research automation to help identify new targets for treatment and disease and expand patient care. Thus, the increasing use of DNA sequencing for clinical diagnosis and drug discovery is expected to propel the market growth over the forecast period.

Get a Free Sample Research Report:https://www.skyquestt.com/sample-request/dna-sequencing-market

DNA Sequencing Market Segmental AnalysisGlobal DNA Sequencing Market is segmented based on Product, Application, Technology, End User, and Region.

Based on Product the DNA Sequencing Market is further sub segmented into Consumable, Instrument, and Service. Based on Application the DNA Sequencing Market is further sub-segmented into Biomarkers and Cancer, Diagnostics, Reproductive Health, Personalized Medicine, Forensics, and Others. Based on Technology the DNA Sequencing Market is further sub segmented into Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real-time Sequencing, Chain Termination Sequencing, and Nanopore Sequencing. Based on End User the DNA Sequencing Market is further sub segmented into Academic & Government Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Hospitals & Clinics. Based on Region, the DNA Sequencing Market is further sub-segments into North America, Europe, Asia Pacific, Latin America, and MEA .

Near-Term Horizon Accelerating Precision Medicine (Next 4-5 Years)Over the next decade, DNA sequencing could be more and more incorporated into global health care structures, transforming how diseases are dealt with and avoided. Furthermore, advances breakthroughs in bioinformatics and synthetic intelligence will extend DNA sequencing into broader fields such as agriculture and forensics. Whole-genome sequencing may need to grow to be commonplace, permitting actual-time tracking of disease development, early detection of conditions, and superior genome-enhancing solutions which include the CRISPR.

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/dna-sequencing-market

This report covers the following players:• Illumina, Inc.• Thermo Fisher Scientific, Inc.• Pacific Biosciences of California Inc.• BGI Group• Oxford Nanopore Technologies Ltd.• Qiagen N.V.• F. Hoffmann-La Roche Ltd.• PerkinElmer Inc.• Agilent Technologies, Inc.• Eurofins Scientific SE• Zymo Research Corp.• Hamilton Company• Genewiz Inc.• Macrogen Inc.• DNASTAR Inc.• GENEWORLD• Bio-Rad Laboratories Inc.• BioChain Institute Inc.• Beckman Coulter Inc.• Novogene Corporation Hamilton Company

Long-Term Vision Revolutionizing Global Healthcare (Next 10 Years)Over the next 4-5 years, the DNA sequencing market will see a rise in the use of precision medicine. This will lead to faster diagnosis of genetic diseases, cancer treatments and personalized therapies, and transform the patient care. The healthcare industry will see an increasing reliance on genomics for drug prevention and risk prediction, while pharmaceutical companies will use DNA sequencing for drug development, for clinical trials and drug development.In October 2022, PacBio announced the release of two genome sequencing systems, the Revio long-read sequencing system and the Onso short-read sequencing system. In March 2022, Element Biosciences released technical specifications for its long-awaited Aviti DNA sequences. The new benchtop instrument employs a riff on sequencing-by-synthesis chemistry that Element says reduces reagent usage, leading to costs of approximately USD 7 per Gb.

View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/dna-sequencing-market

This report covers the following segments:

A. Type1. Consumable2. Instrument3. Service

B. Application 1. Biomarkers2. Cancer3. Diagnostics4. Reproductive Health5. Personalized Medicine6. Forensics7. Others

C. Technology1. Synthesis2. Ion Semiconductor Sequencing3. Sequencing by Ligation4. Pyrosequencing5. Single Molecule Real-time Sequencing6. Chain Termination Sequencing7. Nanopore Sequencing

D. End User1. Academic & Government Research Institutes2. Pharmaceutical Companies3. Biotechnology Companies4. Hospitals & Clinics

Empowering Precision Medicine the Future of DNA SequencingThe DNA sequencing market is growing rapidly, driven by technological advancements, cost reductions, and increasing applications in the healthcare, research, and biotechnology. While precision medicine is increasingly evident, demand for sequencing technologies continues to rise, creating opportunities for innovation. The combination of next-generation sequencing systems with artificial intelligence and bioinformatics will dramatically increase the accuracy and speed of genomic analysis. As standard medicine advances, DNA sequencing plays an important role in disease diagnosis, development of targeted therapies, and advanced genetic research.

Related Report:Next Generation Sequencing Market is growing at a CAGR of 18.5% in the forecast period (2024-2031).

About Us:SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Visit Our Website: https://www.skyquestt.com/

Mr. Jagraj SinghSkyquest Technology Consulting Pvt. Ltd.+1 351-333-4748email us hereVisit us on social media:LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

September 25, 2024, 13:15 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

NEW YORK, Oct. 4, 2024 /PRNewswire/ -- The Dana Foundation today announced the launch of Neurotech Justice Accelerator at Mass General Brigham, an integrated academic health care system and the nation's largest hospital-based research enterprise. The five-year $8.6 million initiative aims to improve equitable access to beneficial neurotechnologies and to mitigate the associated risks in medical and legal settings.

"NJAM was developed to support field building and training to address the ethical implications of scientific advancement," said Caroline Montojo, Ph.D., president and CEO of the Dana Foundation. "For example, emerging diagnostic technologies are likely to affect care or even end-of-life decisions for patients in a 'vegetative state'. Clinicians and legal practitioners need to be aware of the potential and limitations of neuroscience and be equipped to make reasonable judgments given the evidence they provide."

Under a team of renowned practitioners and scholars in neurosurgery, neuroethics, and neurolaw from Massachusetts General Hospital (MGH) – a founding member of Mass General Brigham – Harvard Medical School, and the University of Minnesota, NJAM integrates training in clinical practice, law, ethics, and neuroscience – disciplines that typically operate independently. Programs include:

• interdisciplinary research training on equitable application of beneficial clinical neurotechnologies, and on neuroscience as evidence in court and in criminal justice reform.
• community partnership and advocacy training to facilitate bi-directional learning between NJAM fellows and members of communities likely to be impacted by neurotechnology advancement.

NJAM is part of the nearly $20 million Dana Center Initiative launched earlier this year. It joins the UCLA-CDU Dana Center for Neuroscience and Society and the Dana Program for Neuroscience and Society at Loyola University Chicago.

"Neuroscience is moving forward in exciting ways, often so fast that it outpaces public discourse and training about potential benefits and risks," said Steven E. Hyman, M.D., chairman of the board at the Dana Foundation. "Through the Dana Center Initiative, we hope to catalyze the cultural and institutional shifts needed to fully realize the positive impact of neuroscience while making sure it's applied fairly and responsibly."

Advancing Ethical Application in Clinical SettingsFrom a medical perspective, emerging technologies and new applications of brain imaging, deep brain stimulation, and stimulus-based electroencephalogram hold great potential to improve outcomes for patients with neurologic diseases. They also promise to improve diagnosis and assessment of brain injuries and disorders of consciousness.

NJAM will provide a mixed-methods research training program to accelerate the responsible uptake of neurotechnology in clinical and other contexts. Through community-based participatory research, quantitative and qualitative methods, and big data analysis, NJAM fellows will identify barriers to access, solutions for preventing injustices, and pathways for addressing challenges in brain-based conditions.

"Due in part to lack of training in a clinical setting, some neurotechnologies are applied today in just a few hospitals and clinics throughout the world," said Theresa Williamson, M.D., MPH, assistant professor of neurosurgery and neuroethicist at MGH and Harvard Medical School, and co-director of NJAM. "One of the major aims of NJAM is to ensure more clinicians and medical practitioners are trained to understand the potential of these technologies and how to apply them. Our work through NJAM is about ensuring more patients will benefit from advances in neurotechnology development."

Promoting Responsible Use in Legal SettingsFrom a legal perspective, neurotechnological advances raise questions in areas such as the application of neuroscientific evidence in criminal sentencing and brain injury litigation. NJAM will offer an interdisciplinary neurolaw training program through which participants will identify barriers and opportunities of deploying neurotechnology as evidence in legal settings, collaborate with judges and lawyers, and improve access to neuroscience tools for resource-poor litigants.

"Judges and other legal practitioners are already being presented with evidence drawn from neurotechnologies that raise questions about justice, access, and privacy. This is likely to increase as new capabilities and applications are discovered," said Francis X. Shen, J.D., Ph.D., a member of the University of Minnesota Law School faculty, MGH Hospital Center for Law, Brain & Behavior, Harvard Medical School Center for Bioethics, and co-director of NJAM. Shen, who is an expert in the intersection of law, ethics, neuroscience, and AI, added, "Is it ethical to use this neuroscience information? Will it promote or hinder just legal outcomes? And how do we ensure privacy? Today, legal practitioners have little practical guidance on how to apply group-level neuroscience research to individualized legal decisions. NJAM will train the next generation of neurolaw practitioners to change that."

Engaging Community Partnership Recognizing the important role local organizations play in supporting members of their communities, NJAM will also equip scientists with skills to listen deeply to members of communities affected by novel neurotechnologies and share their science in a way that informs policy solutions.

"It's critical to train the next generation of scientists to engage with communities to incorporate their voice into research priorities," said Gabriel Lázaro-Muñoz, Ph.D., J.D., assistant professor and neuroethics researcher at Harvard Medical School and the MGH Department of Neurosurgery, and co-director of NJAM. Lázaro-Muñoz combines his background in neuroscience, law, and bioethics to examine ethical, legal, and social implications of emerging technologies. "We seek to increase the role of patients and community members in the responsible development of neurotechnology. Training will enable scientists to create solutions with, rather than for, community members."

About The Dana FoundationThe Dana Foundation advances neuroscience that benefits society and reflects the aspirations of all people. We explore the connections between neuroscience and society's challenges and opportunities, working to maximize the potential of the field to do good. Find out more at dana.org.

SOURCE Dana Foundation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

The purchase of Old River Place comes on the heels of five previous 2024 acquisitions made by Bascom.  Bascom remains highly active pursuing new acquisitions throughout the United States and intends to continue portfolio expansion through year-end.

Bascom has been one of the most active apartment buyers in California and the Central Valley partnering with institutional and private capital. Prior to purchasing Old River Place, Bascom had acquired 130 multifamily properties and 20,773 units in California, with 25 of those properties and 3,619 units located in the Central Valley. Over the past six months, Bascom has completed roughly $265 million in multifamily acquisitions nationwide.

Joe Ferguson, Acquisition Manager for Bascom, states "Old River Place is a uniquely well-constructed build to rent community in the affluent area of Southwest Bakersfield. Each unit at the property has an attached two-car garage and dedicated outdoor space. Old River Place adds another well-located, recently built asset to the Bascom portfolio that should perform well in a market that needs housing.  The high-interest rate environment and the resulting increased monthly mortgage payment has only added to the desirability of these build to rent communities. The Bakersfield market continues to demonstrate attractive multifamily fundamentals, and we are excited to strengthen our footprint in one of California's fastest growing regions."

Located within the desirable Southwest submarket of Bakersfield, Old River Place offers residents a low-density single-family residential style community with an attractive unit mix of two- and three-bedroom units.  The property is adjacent to affluent Bakersfield neighborhoods such as Seven Oaks and Hagan Oaks, provides residents easy access to retailers like Sprouts, Trader Joes, Lululemon and Target, and accessibility to major employment drivers such as Cal State Bakersfield and Dignity Health – Mercy Hospital.

Bascom's Lee Nguyen, Senior Vice President of Portfolio Operations, adds "Old River Place has been well-maintained while demonstrating consistent rental demand. As part of our strategic renovation program, Bascom intends to upgrade unit interiors with new appliances, countertops, backsplash, cabinetry, as well as enhancing the property's exteriors and community amenities. All of the units remain in a classic or original condition, giving our operations team considerable room to add desirable elements while providing residents an affordable housing option in a well located, highly desirable rental community."

Bakersfield has been one of California's best performing apartment markets, highlighted by consistent occupancies above 95%. The strong fundamentals have been driven by limited new supply, high population growth (no large California city has grown more than Bakersfield over the last five years), and a diversifying economy.  The city serves as a hub for various industries including agriculture, healthcare, energy, manufacturing, and a growing logistics industry. Bakersfield's central location in California's San Joaquin Valley makes it a key transportation hub. It's well-positioned along major highways like Interstate 5 and State Route 99, facilitating efficient movement of goods between Northern and Southern California, as well as connecting to other states. As a result, major businesses continue to invest in Bakersfield for future growth. Notably, Tesla has plans to build the world's largest supercharger station and Wonderful Co. recently announced a major expansion of their industrial park, which is projected to support 50,000 jobs.

About Bascom:  Bascom is a private equity firm specializing in value-added multifamily, commercial, and non-performing loans and real estate related investments and operating companies. Bascom sources value-added and distressed properties including many through foreclosure, bankruptcy, or short sales and repositions them by adding extensive capital improvements, improving revenue, and reducing expenses by realizing operational efficiencies through implementation of institutional-quality property management. Bascom, founded by principals Derek Chen, Jerry Fink, and David Kim, is one of the most active and seasoned buyers and operators of apartment communities in the U.S. Since 1996, Bascom has completed over $22.0 billion in multifamily value-added transactions encompassing 358 multifamily properties and over 105,000 units. Bascom's commercial transaction volume is $5.8 billion in total and amounts to over 23.4 million square feet. Bascom has ranked among the top 50 multifamily owners in the U.S. Bascom's subsidiaries and joint ventures include the Bascom Value Added Apartment Investors, Shubin Nadal Associates, Spirit Bascom Ventures, REDA Bascom Ventures, Bascom Northwest Ventures, Bascom Arizona Ventures, Harbor Associates, Village Partners Ventures, and Realm Group. Bascom's subsidiaries also include Premier Workspaces, one of the largest privately held executive suite, coworking and shared workspace companies in the U.S. For additional information, please visit www.bascomgroup.com.

Contact: Joe Ferguson / Jim Singleton                                                                    Tel: 949-955-0888 ext.120 / 116Email: [email protected] 

SOURCE The Bascom Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

SAN ANTONIO, Sept. 18, 2024 /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS)—one of the nation's largest homebuilders, an industry leader in online home sales, and the highest-ranked homebuilder on Newsweek's list of America's Most Trustworthy Companies 2024—is pleased to announce three upcoming ribbon-cutting ceremonies with the San Antonio Chamber of Commerce to debut new model homes at three anticipated communities: Agave (Southeast San Antonio), Applewhite Meadows (South San Antonio), and Hacienda (South San Antonio).

Spanning 200,000 square feet of light industrial space across five buildings, Merritt at Gate Parkway offers immediate leasing opportunities with spaces starting at 3,500 square feet. Zoned as Industrial Business Park (IBP), the site offers 14-foot clear heights and ample parking, providing flexible industrial space for a variety of businesses.

At the time of the acquisition, the Southside Duval County submarket reported a light industrial vacancy rate of less than three percent. Previously, the development had transitioned to a single-story office layout, but with increasing demand for small-bay light industrial spaces, Merritt Properties identified a prime opportunity to convert the property to Class A light industrial use. Plans are already underway to enhance the property by installing drive-in docks and further upgrading the facilities to meet modern industrial standards.

Merritt at Gate Parkway is home to established tenants, including DB Structured Products and MMI.

"With its prime location, we are thrilled to expand our light industrial presence in Jacksonville with the acquisition of Merritt at Gate Parkway, which underscores our ongoing commitment to providing quality industrial spaces in key markets," said Pat Franklin of Merritt Properties. "We are dedicated to enhancing the park's infrastructure to ensure that both current and future tenants benefit from a premier industrial environment."

Gary Swatko of Merritt Properties highlighted the significance of the site's redevelopment potential, "Merritt at Gate Parkway represents a tremendous opportunity for us to restore top-tier industrial space in a high-demand area. The potential for redevelopment is vast, and we're eager to transform this site into a modern, thriving industrial hub. This acquisition is a key component of our strategy to support Jacksonville's economic growth by providing the essential infrastructure businesses need to succeed."

This acquisition marks a significant step in Merritt Properties' broader expansion in Jacksonville, where the company already owns and operates Imeson Landing Business Park, another five-building industrial park. Plans are underway to expand Imeson Landing with three additional buildings. Additionally, Merritt Properties owns land in Clay County for the future development of Oakleaf Commerce Center and acquired Magnolia Park, a three-building business park, during its initial expansion into Jacksonville in 2021. Merritt holdings in Jacksonville now exceeds 500,000 square feet of light industrial in just two years of being in the market.

For leasing inquiries or more information about Merritt at Gate Parkway, please visit www.merritt-gateparkway.com.

About Merritt Properties 
Established in 1967, Merritt Properties is a full-service commercial real estate firm with over 21 million square feet of office, warehouse, industrial, retail and build-to-suit throughout Maryland, Florida, North Carolina and Virginia. Our company is committed to "Creating Homes for Businesses" and providing the highest quality service to our customers. Merritt is unique in that we build for the long-term and manage all of our properties internally. Therefore, we value trust, integrity, respect, and lasting relationships over short-term gain. And, because every Merritt employee is also an owner of the company, we each have a vested interest in the success of our customers. That's why we are responsive and committed to honest and fair business dealings that grow customer relationships into long-term partnerships. For more information, visit www.merrittproperties.com.

SOURCE Merritt Properties, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

PASADENA, Calif., Sept. 18, 2024 /PRNewswire/ -- Familiar Touch, a "coming of (old) age" film that won the Luigi de Laurentiis Lion of the Future prize for best first film at the 81^st Venice International Film Festival Orizzonti Competition, was filmed at Villa Gardens, a Front Porch Retirement Community located in Pasadena, and included residents and staff among its cast and crew.

Written and directed by Sarah Friedland, who won for best director and starring Kathleen Chalfant, who received the award for best actress, Familiar Touch follows an octogenarian woman's transition to life in assisted living as she contends with her conflicting relationship to herself and her caregivers amidst her shifting memory, age identity, and desires.

In her acceptance speech, Friedland said, "None of this exists without the residents and staff of Villa Gardens Continuing Care Retirement Community who invited us into their stories, home and workplace."

In the five weeks leading up to principle photography, Friedland and members of her film crew and cast led workshops on different aspects of filmmaking for Villa Gardens residents, such as scriptwriting, cinematography, acting, editing and art direction. "Each week we would shoot a very short film, and the residents who participated in the workshop would rotate roles, so if you were directing one week you were acting or designing the next. By the end of it, everyone who participated got to try every aspect of filmmaking," said Friedland.

Residents and staff also participated in the film itself, both on camera and behind the scenes. Dick Myers, a retired Navy pilot who had a career in consulting, real estate, and software development and had never acted before, took on a non-speaking role as a resident in a memory care neighborhood, appearing in several scenes. Resident Lisa Tanahashi worked with the Art Department, meeting with other residents to select personal pieces of art to be displayed in various scenes. The process of collecting the art and hearing the stories behind each piece added a special dimension to the movie, Tanahashi shared.

"Something about this experience changed us," said Tanahashi. "We walk a little taller, we feel things a little deeper, we got to know each other, and we got to laugh with and at each other as we were going through this unfamiliar process."

According to the Director's Statement, "By turning a retirement community into a professional film set and intergenerational artist residency, we wanted to challenge the perception of care facilities as depressing places devoid of creativity, and support older adults' self-expression while inviting their, and care workers', collaboration in our anti-ageist character study."

More information about Familiar Touch can be found at https://www.familiartouchfilm.com/.  

About Villa Gardens Villa Gardens is a Front Porch Retirement Community located in Pasadena, California. With a full continuum of care and a wide array of amenities and services, Villa Gardens builds community by cultivating meaningful relationships and experiences that respond creatively to changing needs. Learn more at https://frontporch.net/community/villa-gardens/.

About Front Porch Communities and ServicesFront Porch is a dynamic not-for-profit organization, dedicated to empowering individuals to live connected and fulfilled lives through community and innovation. In support of this vision, Front Porch provides high quality, accessible and affordable human services through senior living communities, affordable housing communities and other programs and services throughout the United States.

Media Contact: Laura Darling, VP of Communications[email protected] 818-482-7597

SOURCE Front Porch

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

Augusta Grove Logistics Park is in the Greenville-Spartanburg industrial market, with easy access to the I-85 logistics corridor and I-185, Greenville's perimeter highway.

Building 1 was developed as a Build-to-Suit facility for Haier, a GE Appliances company that produces home appliances such as refrigerators, washing machines, and air conditioners. The facility will serve as a hub for warehousing and distribution of products from Haier's manufacturing sites in Alabama, Georgia, Kentucky, South Carolina, and Tennessee, as well as imported goods from the Port of Charleston.

The park's proximity to the Greer Inland Port rail line played a significant role in Haier's facility location decision. Additionally, the facility is 130 miles from GE Appliances' new water heater manufacturing plant in Camden, South Carolina, which supports Haier's growth in the Greenville area.

Building 1 is a 584,820-square-foot cross-dock logistics facility. Constructed with concrete tilt-wall, the building features a 36-foot clear height, LED lighting, and a modern glass storefront. It includes 123 dock-high doors, 2 ramped drive-in doors, and 54-foot by 50-foot column spacing with 60-foot speed bays. Provident's Case Van Lare, Managing Director, and Hunter Graham, Director of Southeast Industrial Development & Acquisitions, led the project with Cooper Construction serving as the general contractor.

Augusta Grove Logistics Park was developed through a joint venture, including CrossFirst Bank, TPA Group and Sweetwater Capital. Reflecting on the successful partnership, Hunter Graham of Provident stated, "This project's success is a testament to the continued demand for institutional quality assets strategically located in the Southeast."

Provident has significantly expanded its industrial portfolio, with 7.9 million square feet currently under construction or in pre-development across Texas, Arizona, and the Carolinas.

About Provident

Provident is a privately held real estate and investment firm with over three decades of success across multiple market cycles driven by foresight, experience, and adaptability to changing markets. Provident focuses on delivering exceptional risk-adjusted returns to investor partners through development of opportunistic and value-add strategies. Since its founding in 1991, Provident has developed or invested in over $5.9 billion in real estate projects nationwide. For more information, please visit www.providentrealty.net.

CONTACT: Hunter Graham, [email protected]

SOURCE Provident Realty Advisors, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Founded in Q4 2023 by Brendan Van Deventer and Tony Ferrell, in partnership with Bascom, CRES has grown rapidly and is now active in 18 states, overseeing more than 7,000 multi-family units. CRES's hands-on partnership model ensures their clients receive support throughout every stage of the investment lifecycle, no matter where they sit in the capital stack. By actively listening to their clients' unique financial objectives and combining them with comprehensive market analysis, CRES crafts tailored scopes and plans that address their clients' specific needs.

With over 25 years of combined multi-family experience, the leadership team has successfully repositioned over 100 assets and managed more than 35,000 multi-family units. CRES is dedicated to maximum transparency, expert guidance, and strategic insights to give our clients the tools needed to maximize their investments as a fiduciary to their investors, whether they are a GP, LP, or Lender.

"CRES will continue implementing the best practices in real estate investment, operations, and asset management that we've gained from working for industry-leading operating companies and institutions," said Co-Founders Brendan and Tony.

More information can be found at cre-strategies.com, or reach them at 469-342-8780.

About Bascom: Bascom is a private equity firm specializing in value-added multifamily, commercial, and non-performing loans and real estate related investments and operating companies. Bascom sources value-added and distressed properties including many through foreclosure, bankruptcy, or short sales and repositions them by adding extensive capital improvements, improving revenue, and reducing expenses by realizing operational efficiencies through implementation of institutional-quality property management. Bascom, founded by principals Derek Chen, Jerry Fink, and David Kim, is one of the most active and seasoned buyers and operators of apartment communities in the U.S.  Since 1996, Bascom has completed over $22.0 billion in multifamily value-added transactions encompassing 358 multifamily properties and over 105,000 units. Bascom's commercial transaction volume is $5.8 billion in total and amounts to over 23.4 million square feet. Bascom has ranked among the top 50 multifamily owners in the U.S. Bascom's subsidiaries and joint ventures include the Bascom Value Added Apartment Investors, Shubin Nadal Associates, Spirit Bascom Ventures, REDA Bascom Ventures, Bascom Northwest Ventures, Bascom Arizona Ventures, Harbor Associates, Village Partners Ventures, CRES, and Realm Group. Bascom's subsidiaries also include Premier Workspaces, one of the largest privately held executive suite, coworking and shared workspace companies in the U.S. For additional information, please visit www.bascomgroup.com.

Contact:Tony Ferrell and Brendan Van Deventer Tel: 469 342 8780 Email: [email protected]

SOURCE The Bascom Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Shopoff secured California Coastal Commission approval in July 2024. With City Council approval now in place, plans for this vibrant future community in Huntington Beach can now move into the next stage of development. The project anticipates approximately 200+ for-sale single-family detached and attached homes, a 50-unit affordable multifamily community, and a 215-key boutique hotel with 19,000 square feet of retail.

"We are grateful to the city of Huntington Beach for their support of this project, which we believe will be a fantastic addition to the city, brightening this historically blighted stretch of the coast," explained Shopoff President and CEO William Shopoff. "This approval marks a major milestone for the project, and we'd like to thank all our many supporters who saw the immense value in this new community, including affordable housing advocates, labor unions, construction and hotel workers, Huntington Beach residents and businesses, as well as the California Coastal Commission. Being able to build such as diverse coalition of groups to support this project ultimately led to our ability to garner unanimous support."

This new community in southeastern Huntington Beach will provide quality housing for Huntington Beach residents, with a much-needed affordable housing component. This includes a first-of-its-kind program which will dedicate 50% of the affordable housing to hotel workers on-site and within the coastal region of Huntington Beach. Shopoff believes this innovative program is vitally important to the success of this project, as it will allow workers to live in the city where they are employed, avoiding lengthy daily commutes.

Shopoff intends to break ground on the project in summer/fall 2025.

About Shopoff Realty InvestmentsShopoff Realty Investments is an Irvine, California-based real estate firm with a 32-year history of value-add and opportunistic investing across the United States. The company primarily focuses on proactively generating appreciation through the repositioning of commercial income-producing properties, the entitlement of land assets, and development projects. The 32-year history includes operating as Asset Recovery Fund, Eastbridge Partners, and Shopoff Realty Investments (formerly known as The Shopoff Group). Performance has varied in this time frame, with certain offerings generating losses. For additional information, please visit www.shopoff.com or call (844) 4-SHOPOFF.

DisclosuresThis is not an offering to buy or sell any securities. Such an offer may only be made through the offering memorandum to qualified purchasers. Any investment in Shopoff Realty Investments programs involves substantial risks and is suitable only for investors who have no need for liquidity and who can bear the loss of their entire investment. There is no assurance that any strategy will succeed to meet its investment objectives. The performance of this asset is not indicative of future results of other assets. Securities are offered through Shopoff Securities, Inc. member FINRA/SIPC, 18565 Jamboree Road, Suite 200, Irvine, CA 92612.

Contact:Jill SwartzSpotlight Marketing Communications949.427.1389[email protected]

SOURCE Shopoff Realty Investments

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

PALM BEACH GARDENS, Fla. , Aug. 28, 2024 /PRNewswire/ -- The Richman Group, an innovator in multifamily development, and Richman Property Services, a national leader in multifamily management, today announced the opening of its prestigious Ultra Signature community, The Marc, situated in the upscale enclave of Palm Beach Gardens.

The Marc stands as a beacon of sophistication, boasting 396 opulent homes within a contemporary high-rise setting. It is characterized by unparalleled premium amenities and cutting-edge, in-home technologies. Nestled at 3955 Design Center Drive, this exceptional community strategically situates residents in close proximity to exclusive dining destinations, upscale shopping, top-rated schools, scenic parks, culinary festivals, minor league baseball, spring training facilities, and an array of entertainment venues.

"From its meticulously crafted homes to start-of-the-art amenities, The Marc envelops residents with innovations that redefine ultra-modern luxury," said Theresa Eastwood David, President Richman Property Services, the property management division for the Richman Group. "The thoughtful property design captures the coastal Florida ambiance, catering to dynamic lifestyles while also providing a tranquil setting and plenty of opportunities for relaxation."

The Marc features a range of studio, one-, two-, and three-bedroom homes, spanning from 530 to 1,460 square feet. The smart home technology package includes programmable thermostats and electronic door locks, complemented by LED lighting throughout. The kitchens showcase high-end design with sought-after dual-tone cabinetry, stainless steel appliances, white quartz countertops, tile backsplashes, and stylish black pendant lighting over kitchen islands and peninsulas. Living areas and bedrooms boast wood-inspired vinyl plank flooring, while bathrooms exude luxury with granite countertops, showers featuring tile surround, and porcelain tile flooring. Most bedrooms are adorned with walk-in closets and expansive windows, while select homes offer large terraces.

All residents can indulge in an expansive resort-style pool with lap lane and water feature and surrounded by a sun deck with cabanas. A fully equipped barbeque area incorporates an oversized outdoor TV and lounge seating. Four-legged residents can make the most of a completely shaded dog park with pet-specific structures. An interior courtyard beckons with hammocks, water fountain and fire pit, and an exterior courtyard showcases garden sculptures and natural areas with inviting benches.

Indoor amenities rival the finest with a clubroom boasting a kitchenette and bar area, pool table, and seating overlooking the pool deck. A state-of-the-art fitness center comes equipped with Life Fitness, Free Motion and Peloton equipment, The Mirror and Wellbeats technology, and a designated yoga/spin area. A business center with computer stations, private offices and a conference room easily accommodates remote-work needs. Golf enthusiasts can take advantage of a golf simulator featuring a Trackman system, as well as a putting green. Other notable amenities include a library with fireplace and TV, meditation room, storage rooms, and 606 parking spaces — including 16 spaces with EV charging stations.

The Marc affords excellent regional connectivity, with Interstate Highway 95 just blocks away, leading north to Port St. Lucie and Melbourne, and south to West Palm Beach, Boca Raton and Miami. Major area employers include Florida Crystals Corp, Pratt & Whitney, Sikorsky, Aerojet Rocketdyne, Palm Beach County School District, Tenet Healthcare, NextEra Energy and Florida Atlantic University.

Click here for more information on The Marc.

About The Richman GroupFounded by Richard Paul Richman in 1986, The Richman Group consistently maintains one of the top 10 largest portfolios in multifamily. With more than 2,000 properties in 49 states, over 166,500 apartment homes and 12 offices spread across the country, the firm conducts a wide range of development, equity investment, mortgage financing, asset management and property management activities. The Richman Group has a major presence in both the luxury rental apartment and affordable housing sectors. Its objective is to create a great residential experience for all residents, and optimize economic returns for developer clients, partners and investors. For more information, please visit www.TheRichmanGroup.com.

Media Contact:Marlena DeFalco LinnellTaylor Marketing[email protected] 

SOURCE The Richman Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

AUBURN, Calif., Sept. 18, 2024 /PRNewswire/ -- Homeowners in Auburn, the county seat of Placer County, can now access Property Assessed Clean Energy (PACE) home improvement financing through industry leader Home Run Financing (HRF), in accordance with a recent vote by the Auburn City Council. The Placer County Board of Supervisors voted in December to extend the program, originally approved in 2020, for another five years in unincorporated areas of the county, showing confidence in the program and an appreciation for its benefits for Placer County homeowners. The county's largest city, Roseville, has also approved PACE financing for its residents.

PACE financing can be used to fund renewable energy, and energy and water efficiency upgrades, as well as earthquake resiliency. Auburn joins more than 340 other cities and towns in California in making PACE Funding available to homeowners.

"With the recent high temperatures in Auburn and Excessive Heat Warning through the region, Auburn homeowners need funding options to upgrade their homes to be more resilient and energy-efficient," said Home Run Financing CEO, Robert Giles. "PACE can help build the community's resiliency to such extreme weather events. It can also allow more homeowners to add solar panels, energy efficient HVAC, and other efficient and renewable energy systems to lower their utility bills and reduce the region's carbon emissions."

PACE Financing is available only through registered and trained contractors. State legislation and regulation by the state Department of Financing Protection and Innovation (DFPI) provides robust consumer protections for homeowners.

Drought remains a perennial problem in California and more and more homeowners are looking for additional ways to fund home upgrades to save water. California homeowners are also looking for ways to reduce utility bills in the face of rising energy costs, both by installing renewable energy systems like solar panels, and by installing more efficient (less leaky) windows and doors and roofs. PACE Financing is specifically designed to be used for such water and energy saving projects.

The PACE financing model provides the strongest consumer protections of any home improvement financing product, with homeowner identity verification measures; recorded confirmation of terms calls conducted in English or Spanish to ensure the homeowner understands the financing; a further recorded call in English or Spanish to verify the project is complete before the contractor gets paid; third-party inspection of completed projects; rigorous contractor oversight and training; and additional protections for the elderly and low-income homeowners, among several other stringent consumer protection measures.

In the eight years Home Run Financing (previously PACE Funding Group) has been operating in California, the company has provided more than $555 million in PACE financing for more than 18,000 home improvement projects across the state. These projects have set in place greenhouse gas reductions, over the lifetime of the upgrades, of 177,800 metric tons, equivalent to taking more than 42,000 cars off the road for a year or powering more than 23,000 homes for a year. The water efficiency upgrades have set in place the conservation of 191 million gallons of water, equivalent to filling 9,000 backyard pools or taking 9 million five-minute showers. HRF-financed projects have created 5,000 good-paying jobs across the state.

Learn more at www.homerunfinancing.com.

CONTACTSevern Williams510-336-9566[email protected]

SOURCE Home Run Financing

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

Details on the poster presentations at SITC 2024 are below:

Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma
Publication Number: 329Session Date & Time: Friday, Nov. 8, 2024 Location: Exhibit Halls A B George R. Brown Convention Center

Title: A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumorsPublication Number: 659Session Date & Time: Friday, Nov. 8, 2024Location: Exhibit Halls A B George R. Brown Convention Center

The posters presented at SITC 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications/ following the start of the poster session.

About Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Cautionary Note on Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, (i) Carisma's ability to realize the anticipated benefits of its pipeline reprioritization and corporate restructuring, (ii) Carisma's ability to obtain, maintain and protect its intellectual property rights related to its product candidates; (iii) Carisma's ability to advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials and with its current financial and human resources; (iv) Carisma's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; (v) Carisma's ability to realize the anticipated benefits of its research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations; (vi) regulatory requirements or developments and Carisma's ability to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities related to its product candidates; (vii) changes to clinical trial designs and regulatory pathways; (viii) risks associated with Carisma's ability to manage expenses; (ix) changes in capital resource requirements; (x) risks related to the inability of Carisma to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; and (xi) legislative, regulatory, political and economic developments.

For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's other recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Investors:Shveta DigheHead of Investor Relations[email protected]

Media Contact:Julia Stern(763) 350-5223[email protected]

SOURCE Carisma Therapeutics Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

The newly acquired properties include two buildings in Fort Lauderdale and one in Pompano Beach. The Fort Lauderdale facilities, strategically located at the intersection of I-95 and the Florida Turnpike, offer a combined 64,687 square feet of prime industrial space. The 37,351-square-foot Pompano Beach property boasts a prominent location fronting I-95. All properties benefit from close proximity to downtown Fort Lauderdale and the Fort Lauderdale Executive Airport, with notable tenants in the area including Amazon, AT&T, and General Electric.

"The strong economic and population growth in Broward County, coupled with excellent connectivity to major highways, airports, and seaports, makes these acquisitions a valuable addition to our South Florida portfolio," said Tyler McElroy, Dalfen's Market Officer for Florida.

Chris Segrest, Regional SVP of the Southeast Region, added, "Dalfen Industrial remains committed to expanding our footprint in South Florida due to the region's strong market fundamentals. We look forward to continuing our focus on acquiring and developing last-mile properties in this key market."

About Dalfen Industrial

Dalfen Industrial LLC, headquartered in Dallas, is one of the largest privately owned industrial real estate firms in the United States and is a leader in the last-mile property sector. The company focuses on strategically located urban infill warehouses and distribution facilities, owning and operating over 55 million square feet of premier industrial properties nationwide. For more information, visit www.dalfen.com.

Media Contact:
[email protected]

SOURCE Dalfen Industrial

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Orthobiologics Market

Orthobiologics Market size was valued at USD 6.43 billion in 2023 to USD 9.87 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2024-2031).

WESTFORD, MA, UNITED STATES, September 25, 2024 /EINPresswire.com/ -- Global Orthobiologics Market size was valued at USD 6.1 billion in 2022 and is poised to grow from USD 6.43 billion in 2023 to USD 9.87 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2024-2031).

The rise in popularity and success rate of orthobiologic techniques for multiple treatments is considered one of the key drivers of this global market. An investigation by Manchester Metropolitan University's Professor Mark Slevin, a specialist in cell pathology, showed that about 70% of patients who receive orthobiologic therapy have positive results. According to the overall findings, more than 70% of the treated patients report notable benefits, including decreased pain and enhanced mobility.

The global orthobiologics market has witnessed an increase in demand due to the development of regenerative medicine coupled with a surge in minimally invasive procedures. This is due to there are more orthopedic cases than ever before, stem cell therapies continue to gain popularity while biomaterials are continuously being utilized for tissue repair and regeneration. For this reason, these elements have led to an increase in the scope of this field as well as technological advancement.

Get a Free Sample Research Report:
https://www.skyquestt.com/sample-request/orthobiologics-market

Orthobiologics Market Segmental AnalysisGlobal Orthobiologics Market is segmented by Product, Application, End User and Region.

Based on Product, the market is segmented into Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, Plasma-Rich Protein, Bone Marrow Aspirate Concentrate. Based on Application, the market is segmented into Osteoarthritis and Degenerative Arthritis, Spinal Fusion, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications. Based on End User, the market is segmented into Hospitals, Orthopedic Clinics, & Ambulatory Care Centers, Research & Academic Institutes, Dental Clinics and Facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Spinal Surgery Efficiency and Market Evolution Over the Next Five YearsIn August 2024, Zimmer Biomet disclosed the introduction of an advanced bone graft substitute that aims at improving spinal surgical efficacy. In this regard, it is anticipated that this latest product will have much influence on ortho biologics by factoring into better patient results and promote faster use of state-of-the-art regenerative alternatives within the next four to five years.

In July 2024, the partnership between a leading biotech company and Medtronic to set up socially relevant stem cell therapies for bone injuries is likely to transform the industry entirely. The collaboration will provide customized offering, perhaps redefining orthobiologics and consequently resulting in massive market expansions and technological innovations in subsequent years.

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/orthobiologics-market

The report covers the following players:• Medtronic plc• Stryker Corporation • Globus Medical, Inc. • Orthofix International N.V. • RTI Surgical, Inc. • Kuros Biosciences Ltd. • Bioventus LLC • Nuvasive, Inc. • Seaspine Holdings Corporation • Arthrex, Inc. • Xtant Medical Holdings, Inc. • Sanofi S.A. • Smith & Nephew plc • Integra LifeSciences Holdings Corporation • Anika Therapeutics, Inc. • Alphatec Spine, Inc. • Orthocell Ltd. • MiMedx Group, Inc. • Orthofix Medical Inc. • Bone Therapeutics SA

Game-Changing Acquisition and its Decade-Long Impact on Regenerative MedicineIn September 2024, Stryker Corporation's acquisition of a prominent regenerative medicine company is poised to revolutionize the field of orthobiologics. This initiative seeks to fuse cutting-edge cellular therapies with biomaterials, which may alter treatment methods and stimulate remarkable development and progress in this market for the next ten years.

In June 2024, the global launch of Smith & Nephew’s revolutionary bioengineered tissue scaffold is projected to set new industry standards. This breakthrough product, designed for complex orthopedic repairs, promises to enhance patient recovery and expand the market, fueling long-term advancements and setting a new trajectory for orthobiologics in the coming ten years.

New Benchmarks in Tissue Regeneration and Joint Preservation for Next DecadeIn October 2023, Becton Dickinson introduced an advanced collagen scaffold that promises better integration and healing in orthopedic biomaterials. Similarly, in November 2024, AlloSource and a leading European biotech company launched a next-generation allograft aimed at speeding up the regeneration of tissues. Besides this, there are plans for launching Arthrex’s innovative cartilage repair system globally in December 2024 which is expected to redefine joint preservation standards. Collectively, these advancements are anticipated to drive significant market expansion, elevate treatment standards, and foster substantial growth in the orthobiologics sector, transforming patient outcomes and industry practices over the next few years.

View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/orthobiologics-market

This report covers the following segments: A. Product1. Viscosupplementation Products2. Demineralized Bone MatricesB. Application1. Osteoarthritis & Degenerative Arthritis2. Spinal FusionC. End User1. Hospitals2. Orthopedic Clinics3. Ambulatory Care Centers

Rising Patient Satisfaction to Drive Market Dynamics and Future Industry TrendsThat’s all right – you’re not alone. The global orthobiologics market is ready to change beyond recognition due to enormous improvements and higher rates of patients’ welfare. According to some studies, about 70% of patients’ conditions have greatly improved due to orthobiologic therapies – they feel less pain and move better than before. There are also some firms such as Zimmer Biomet, Medtronic, and Smith & Nephew that make ground-breaking inventions in this field, buy-up smaller enterprises and release new medicines at the same time. These developments are expected to reshape treatment paradigms, enhance patient outcomes, and propel market expansion over the next decade. The continued evolution in biomaterials, stem cell therapies, and advanced surgical techniques underscores a promising future for the orthobiologics industry.

Related Report:Knee Replacement Market is growing at a CAGR of 5.67% during the forecast period (2024-2031).

About Us:SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Visit Our Website: https://www.skyquestt.com/

Mr. Jagraj SinghSkyquest Technology Consulting Pvt. Ltd.+1 351-333-4748email us hereVisit us on social media:LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

News Provided By

September 25, 2024, 12:30 GMT

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

The following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2025:

Niels Jacobsen, appointed by William Demant Invest A/S
Patrik Tigerschiöld, appointed by Bure Equity ABPatricia Hedelius, appointed by AMF Fonder & PensionJón Sigurdsson, Chairman of the Board

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 25, 2024.

The Annual General Meeting of Vitrolife AB (publ) will be held on April 29, 2025 in Gothenburg.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board, Box 9080, 400 92 Gothenburg, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Gothenburg, October 4, 2024VITROLIFE AB (publ) 

Contact: Jón Sigurdsson, Chairman of the Board, email: [email protected] Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/election-committee-for-vitrolife-ab--publ-,c4047069

The following files are available for download:

SOURCE Vitrolife AB (publ)

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

The property is a colocation data center fully leased to two high-profile, Fortune 500 companies. One of the tenants is a globally recognized leader in the digital infrastructure industry; the other is a major global telecommunications company and one of the largest wireless carriers in the U.S.

Located in the Denver, Colorado market, the Centennial Data Center spans 2.67 acres and features over 30,000 square feet of space, three generator backup systems, and AC/DC power rooms. Adding to Denver's robust fiber optic infrastructure connecting major U.S. markets, its favorable tax policies and economic incentives further bolster Denver's appeal as a data center investment location.

"We are thrilled to further expand our data center portfolio with the acquisition of the Centennial Data Center, aiming to deliver additional value for our investors. Strategically located in Colorado with top-tier tenants and strong investment fundamentals, the facility is an accretive addition for Aphorio Carter. As the demand for data centers and data processing continues to soar, our ability to successfully execute deals in the technology infrastructure space, like this acquisition, reaffirms our commitment to aggregating a strong portfolio of critical assets in the U.S. and creating value through data center real estate," said John Regan, chief investment officer of Aphorio Carter.

This acquisition marks Aphorio Carter's sixth critical infrastructure real estate purchase within the last two years, bringing the Aphorio Carter portfolio to $193 million in critical infrastructure and data center assets under management.

About Aphorio Carter

Aphorio Carter is a Carter Funds company investing in income-producing, mission-critical infrastructure, data centers, and other high-growth, technology-related real estate. Led by a seasoned team with a track record of acquiring 125 data centers worldwide, Aphorio Carter aggregates and manages portfolios of digital infrastructure assets with strategic value-add opportunities for the private investment funds it sponsors. Together, the principals of Aphorio Carter have over a century of experience in the digital infrastructure space with a history totaling $5.3 billion in deal volume. Aphorio Carter targets acquisitions that are net-leased to creditworthy tenants and include wholesale, enterprise, colocation, edge, switch, and cloud data center properties – the critical real estate that powers the digital age.

Media Contact:Stacy SheedyVice President, Marketing, Carter Funds[email protected]813-358-5982

SOURCE Aphorio Carter

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

Dennis Dietzen, PhD, Dannah Raz, MD, Cindy Salm Bauer, MD, and Tressia Shaw, MD, will each be tasked with growing their divisions, enhancing the services their teams provide and ensuring patient families receive consistent, top-quality care at every site of service across the health system.

"Each of these leaders is strong in their respective area of expertise and I'm confident they will make immediate contributions to the health of our patient families and, in turn, our overall community," said Ashish S. Patel, MD, physician-in-chief. "I'm also proud that we have a focused effort on developing leadership paths for our internal candidates and to see Dannah, Cindy and Tressia step into permanent positions as chief."

Dennis Dietzen, PhD, Division Chief of Pathology and Laboratory MedicineAs chief of the Division of Pathology and Laboratory Medicine and the first Megan Dishop Endowed Chair of Pathology at Phoenix Children's, Dr. Dietzen, who steps into his new role this month, will manage and train all pathology and lab teams. He will also be responsible for recruiting clinicians, expanding the health system's specialized testing capabilities and educating the next generation of pathology and laboratory experts.

His 30-year career has spanned medical directorship and leadership roles in hospital-based, academic and pediatric laboratories. At Phoenix Children's, he will build upon the legacy of former division chief Megan Dishop, MD, who passed away in 2023. Dr. Dishop is credited with enhancing testing capabilities, launching a genomics laboratory and biorepository and helping build labs and teams for new sites of service.

Dr. Dietzen earned his doctorate in biochemistry and molecular biology from Indiana University School of Medicine and completed a fellowship in clinical chemistry and post-doctoral research at Washington University School of Medicine. He is certified by the American Board of Clinical Chemistry, allowing him to direct high-complexity laboratory operations per Centers for Medicare and Medicaid Services regulations.

Dannah Raz, MD, Division Chief of Developmental PediatricsA highly regarded developmental and behavioral pediatrician, Dr. Raz has been part of the health system since 2019. She will continue leading the Division of Developmental Pediatrics at Barrow Neurological Institute at Phoenix Children's after serving in an interim capacity for the past year. Dr. Raz will further expand the division's much-needed services and oversee a growing team of specialists dedicated to helping children with developmental disorders. She will also be actively involved in medical education, serving as the medical student and residency rotation director for developmental pediatrics.

Dr. Raz is highly regarded for her focus on multidisciplinary approaches to diagnosing and treating children with developmental and behavioral conditions such as autism, fragile X syndrome, Down syndrome, ADHD, intellectual disabilities and global developmental delays.

Dr. Raz earned her undergraduate and medical degrees from the University of Arizona. She completed her residency training in pediatrics at Phoenix Children's and her fellowship training in developmental pediatrics at Children's Hospital Colorado. She also has a Master of Public Health degree from the University of Colorado School of Public Health.

Cindy Salm Bauer, MD, Division Chief of Allergy and ImmunologyDr. Bauer has been part of Phoenix Children's medical staff for more than a decade. She founded Phoenix Children's Allergy and Immunology Clinic in 2013 and has served as its medical director since 2019. When the section of allergy and immunology was elevated to a full division earlier this year, Dr. Bauer was appointed interim chief. Under her leadership as division chief, the division will expand its services to a fourth clinical location in the coming year.

Dr. Bauer has also been instrumental in developing the health system's immunohematology and eosinophilic gastrointestinal disease (EGID) clinics. Passionate about understanding the impact of childhood allergies, she has led significant research initiatives, including newborn screening for severe combined immune deficiency and clinical trials in asthma prevention and food allergy treatments.

Dr. Bauer earned her medical degree from the Medical College of Wisconsin. She completed an internship with Aurora Health Care at St. Luke's Medical Center, her residency at Aurora Sinai Medical Center and St. Luke's Medical Center and completed a fellowship at the Medical College of Wisconsin.

Tressia Shaw, MD, Division Chief of Palliative MedicineDr. Shaw has been named division chief of the newly formed Division of Palliative Medicine at Phoenix Children's, which helps families navigate complex medical decisions and end-of-life care.

Part of Phoenix Children's team for more than 20 years, Dr. Shaw was also instrumental in establishing the health system's Complex Care program in 2005 and its Pediatric Palliative Medicine program in 2009.

Dr. Shaw is credited with transforming the Palliative Medicine program at Phoenix Children's and growing the team to include an interdisciplinary group of 15 clinicians who offer comprehensive care to children with life-limiting conditions. The division also recently launched a fellowship program certified by the Accreditation Council for Graduate Medical Education (ACGME) to expand training for specialists in this vital field.

She earned her medical degree from the University of Arizona College of Medicine and completed a combined residency in internal medicine and pediatrics at Banner Good Samaritan Hospital.

These new division chief appointments come at a pivotal time as Phoenix Children's continues to grow both in size and capability, highlighted by the opening of Phoenix Children's Hospital – Arrowhead Campus and several high-profile leadership announcements, including Ashish S. Patel, MD, as physician-in-chief and Blake Bulloch, MD, MBA, as chief medical officer.

About Phoenix Children's Phoenix Children's is one of the nation's largest pediatric health systems. It comprises Phoenix Children's Hospital – Thomas Campus, Phoenix Children's Hospital – East Valley Campus, Phoenix Children's – Avondale Campus, Phoenix Children's Hospital – Arrowhead Campus, four pediatric specialty and urgent care centers, 11 community pediatric practices, 20 outpatient clinics, two ambulatory surgery centers and seven community-service outpatient clinics throughout the state of Arizona. The system provides world-class inpatient, outpatient, trauma, emergency and urgent care and has been serving children and families for more than 40 years. Phoenix Children's Care Network includes more than 1,400 pediatric primary care providers and specialists who deliver care across more than 75 subspecialties. Alongside our colleagues, collaborators and communities, we're elevating pediatric care, education and innovation, so we can all grow healthier together. For more information, visit phoenixchildrens.org. 

SOURCE Phoenix Children's

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In

MILL VALLEY, Calif., Aug. 27, 2024 /PRNewswire/ -- Today, Montgomery Partners, a leading multi-family real estate investment firm, announced the strategic acquisitions of Water's Edge Apartments in Sacramento and Olympic Apartments in Santa Rosa. These acquisitions demonstrate the firm's motivation to identify and capitalize on investment opportunities that exist in California amidst the trend of investors fleeing the state.

"With some investors exiting California to explore greener pastures, so to speak, we have found that there remain phenomenal opportunities in our own backyard. California's population continues to grow with no relief in sight to lower the high barriers to owning a home. We at Montgomery Partners recognize the need for good quality rental housing in well-established markets," said Braden Badger, Vice President of Investor Relations at Montgomery Partners. "The strong economies in Santa Rosa and Sacramento thrive on a number of diverse sectors, and we look forward to continuing to bring our established management expertise to Multifamily communities in these markets."

The Water's Edge Apartments, a two-story garden-style apartment complex comprised of 64 units in the desirable Pocket-Greenhaven neighborhood of Sacramento, was acquired by the firm for $10M. Located with immediate access to Interstate 5 and just across the street from the Sacramento River, residents will have convenient access to the region's largest employment hubs and retail designations. Montgomery Partners plans to invest $2,160,000 into renovations as part of the overall capital improvements budget to upgrade units as they become available in all common areas, improve drought-tolerant landscaping, replace roofs, install signage, install exterior siding, and install lighting. 

The Olympic Apartments, a mid-century two-story garden-style apartment community of 12 units, was purchased for $2.2M. It is located in the sought-after St. Rose Historical Preservation neighborhood of Santa Rosa. Located just blocks from downtown Santa Rosa, within easy walking distance from a wide variety of retail destinations and award-winning schools. Convenient access to Highway 101 provides residents easy access for commuting to Santa Rosas's diverse economic industries. Montgomery Partners plans to invest just over $316,000 into renovations as part of the overall capital improvements budget to upgrade the common areas, landscaping, roof, signage, and building exterior.

These strategic acquisitions further Montgomery Partners' growing portfolio of multifamily assets throughout Northern California. The firm is dedicated to providing residents with high-quality living communities and delivering exceptional investment opportunities to its investors.

For interviews, images, and additional information, please reach out to Kate Wilkins at [email protected].

About Montgomery Partners: Founded in 1984, Montgomery Partners is a fully integrated real estate investment firm whose principals specialize in the identification, acquisition, renovation, and, through an affiliate, Montgomery Capital Management (MCM), the property management of value-add multifamily investments. The company's mission is to secure undervalued properties in high-barrier-to-entry markets which yield maximum profitability for its private equity clients. Montgomery Partners and MCM maintain staff in offices in both Northern and Southern California. MCM performs internal asset management functions and offers direct oversight of property repositioning using highly experienced on-site and regional managers, an accounting/financial staff, plus a hands-on administrative and investor relations support staff. Learn more at montgomerypartners.com.

SOURCE Montgomery Partners

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &Influencers

9k+Digital MediaOutlets

270k+JournalistsOpted In